WO2022065897A1 - 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 신경퇴행성 질환의 치료 용도 - Google Patents
글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 신경퇴행성 질환의 치료 용도 Download PDFInfo
- Publication number
- WO2022065897A1 WO2022065897A1 PCT/KR2021/013005 KR2021013005W WO2022065897A1 WO 2022065897 A1 WO2022065897 A1 WO 2022065897A1 KR 2021013005 W KR2021013005 W KR 2021013005W WO 2022065897 A1 WO2022065897 A1 WO 2022065897A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- disease
- pharmaceutical composition
- conjugate
- seq
- Prior art date
Links
- 230000004770 neurodegeneration Effects 0.000 title claims abstract description 92
- 208000015122 neurodegenerative disease Diseases 0.000 title claims abstract description 90
- 230000000694 effects Effects 0.000 title claims abstract description 75
- 230000001225 therapeutic effect Effects 0.000 title abstract description 16
- 239000013559 triple agonist Substances 0.000 title abstract 3
- 102000051325 Glucagon Human genes 0.000 title description 25
- 229960004666 glucagon Drugs 0.000 title description 25
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title description 24
- 108060003199 Glucagon Proteins 0.000 title description 13
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
- 101100125311 Escherichia coli (strain K12) hyi gene Proteins 0.000 title 1
- 101150039312 GIP gene Proteins 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 205
- 108060003951 Immunoglobulin Proteins 0.000 claims description 104
- 102000018358 immunoglobulin Human genes 0.000 claims description 104
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 49
- 208000024827 Alzheimer disease Diseases 0.000 claims description 41
- 239000008194 pharmaceutical composition Substances 0.000 claims description 41
- 150000001413 amino acids Chemical class 0.000 claims description 40
- 208000018737 Parkinson disease Diseases 0.000 claims description 33
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 33
- 238000011282 treatment Methods 0.000 claims description 32
- 239000002202 Polyethylene glycol Substances 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 29
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 29
- 229920001223 polyethylene glycol Polymers 0.000 claims description 29
- 201000010099 disease Diseases 0.000 claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 25
- 239000000539 dimer Substances 0.000 claims description 21
- 230000002265 prevention Effects 0.000 claims description 21
- 229920001184 polypeptide Polymers 0.000 claims description 18
- 208000024891 symptom Diseases 0.000 claims description 15
- 125000003277 amino group Chemical group 0.000 claims description 13
- 108010005094 Advanced Glycation End Products Proteins 0.000 claims description 11
- 102000003802 alpha-Synuclein Human genes 0.000 claims description 11
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 11
- 230000007423 decrease Effects 0.000 claims description 11
- 230000009467 reduction Effects 0.000 claims description 11
- 206010012289 Dementia Diseases 0.000 claims description 10
- 208000006011 Stroke Diseases 0.000 claims description 10
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 9
- 201000002832 Lewy body dementia Diseases 0.000 claims description 9
- 210000000274 microglia Anatomy 0.000 claims description 9
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 8
- 206010012601 diabetes mellitus Diseases 0.000 claims description 8
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 8
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 8
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 8
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 7
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 7
- 208000023105 Huntington disease Diseases 0.000 claims description 7
- 206010015037 epilepsy Diseases 0.000 claims description 6
- 206010003591 Ataxia Diseases 0.000 claims description 5
- 230000001120 cytoprotective effect Effects 0.000 claims description 5
- 230000003291 dopaminomimetic effect Effects 0.000 claims description 5
- 206010027175 memory impairment Diseases 0.000 claims description 4
- 208000002381 Brain Hypoxia Diseases 0.000 claims description 3
- 230000006378 damage Effects 0.000 claims description 3
- 208000000044 Amnesia Diseases 0.000 claims description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 2
- 208000026139 Memory disease Diseases 0.000 claims description 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 2
- 208000024571 Pick disease Diseases 0.000 claims description 2
- 230000006984 memory degeneration Effects 0.000 claims description 2
- 208000023060 memory loss Diseases 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 108010063919 Glucagon Receptors Proteins 0.000 abstract description 35
- 102100040890 Glucagon receptor Human genes 0.000 abstract description 24
- 239000003814 drug Substances 0.000 abstract description 21
- 230000001965 increasing effect Effects 0.000 abstract description 19
- 102000005962 receptors Human genes 0.000 abstract description 19
- 108020003175 receptors Proteins 0.000 abstract description 19
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 abstract description 17
- 102100039994 Gastric inhibitory polypeptide Human genes 0.000 abstract description 17
- 229940079593 drug Drugs 0.000 abstract description 12
- 239000008280 blood Substances 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 4
- 239000000562 conjugate Substances 0.000 description 162
- 239000000203 mixture Substances 0.000 description 85
- 239000012190 activator Substances 0.000 description 78
- 238000007363 ring formation reaction Methods 0.000 description 68
- 235000001014 amino acid Nutrition 0.000 description 40
- 229940024606 amino acid Drugs 0.000 description 39
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 30
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 29
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 29
- 102100040918 Pro-glucagon Human genes 0.000 description 29
- 235000018417 cysteine Nutrition 0.000 description 25
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 22
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 21
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 21
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 20
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 19
- 210000004556 brain Anatomy 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- 229920000642 polymer Polymers 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 239000000178 monomer Substances 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- 230000006870 function Effects 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 12
- 229960003638 dopamine Drugs 0.000 description 11
- 210000002569 neuron Anatomy 0.000 description 11
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 10
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 10
- 239000000710 homodimer Substances 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 238000010172 mouse model Methods 0.000 description 10
- 238000001543 one-way ANOVA Methods 0.000 description 10
- 238000006722 reduction reaction Methods 0.000 description 10
- 230000009435 amidation Effects 0.000 description 9
- 238000007112 amidation reaction Methods 0.000 description 9
- 230000000875 corresponding effect Effects 0.000 description 9
- 230000036542 oxidative stress Effects 0.000 description 9
- 235000000346 sugar Nutrition 0.000 description 9
- 210000003792 cranial nerve Anatomy 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 125000000524 functional group Chemical group 0.000 description 8
- 125000001151 peptidyl group Chemical group 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 7
- 239000000560 biocompatible material Substances 0.000 description 7
- 210000004002 dopaminergic cell Anatomy 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000001681 protective effect Effects 0.000 description 7
- 210000003523 substantia nigra Anatomy 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 125000003172 aldehyde group Chemical group 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 210000003710 cerebral cortex Anatomy 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 150000001945 cysteines Chemical group 0.000 description 6
- 210000005064 dopaminergic neuron Anatomy 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 6
- 229960003081 probenecid Drugs 0.000 description 6
- 230000001603 reducing effect Effects 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 108010011459 Exenatide Proteins 0.000 description 5
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 5
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 5
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- 208000028389 Nerve injury Diseases 0.000 description 5
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 5
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 210000005013 brain tissue Anatomy 0.000 description 5
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 229960001519 exenatide Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000008764 nerve damage Effects 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 description 5
- 239000000863 peptide conjugate Substances 0.000 description 5
- 238000006268 reductive amination reaction Methods 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- JVJFIQYAHPMBBX-UHFFFAOYSA-N HNE Natural products CCCCCC(O)C=CC=O JVJFIQYAHPMBBX-UHFFFAOYSA-N 0.000 description 4
- 101100505047 Homo sapiens GCG gene Proteins 0.000 description 4
- 101000886868 Homo sapiens Gastric inhibitory polypeptide Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000003920 cognitive function Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000036252 glycation Effects 0.000 description 4
- -1 hydroxy succinimidyl Chemical group 0.000 description 4
- 230000001771 impaired effect Effects 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 210000001577 neostriatum Anatomy 0.000 description 4
- 201000001119 neuropathy Diseases 0.000 description 4
- 230000007823 neuropathy Effects 0.000 description 4
- 230000004224 protection Effects 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 201000006474 Brain Ischemia Diseases 0.000 description 3
- 208000014644 Brain disease Diseases 0.000 description 3
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical group CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 3
- 208000004547 Hallucinations Diseases 0.000 description 3
- 102000003777 Interleukin-1 beta Human genes 0.000 description 3
- 108090000193 Interleukin-1 beta Proteins 0.000 description 3
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical group CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004958 brain cell Anatomy 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 239000008004 cell lysis buffer Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000000593 degrading effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 102000050325 human granulocyte inhibitory Human genes 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000004766 neurogenesis Effects 0.000 description 3
- 230000001272 neurogenic effect Effects 0.000 description 3
- 230000016273 neuron death Effects 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000002688 persistence Effects 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 3
- 238000010825 rotarod performance test Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 102000013498 tau Proteins Human genes 0.000 description 3
- 108010026424 tau Proteins Proteins 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 2
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 2
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000788682 Homo sapiens GATA-type zinc finger protein 1 Proteins 0.000 description 2
- 101001015516 Homo sapiens Glucagon-like peptide 1 receptor Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 2
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102000012419 Presenilin-2 Human genes 0.000 description 2
- 108010036908 Presenilin-2 Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- RFBKULCUBJAQFT-BIIVOSGPSA-N Ser-Cys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CS)NC(=O)[C@H](CO)N)C(=O)O RFBKULCUBJAQFT-BIIVOSGPSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001299 aldehydes Chemical group 0.000 description 2
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 238000009227 behaviour therapy Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229920000249 biocompatible polymer Polymers 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000003925 brain function Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000005786 degenerative changes Effects 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 150000003951 lactams Chemical group 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000028252 learning or memory Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000015654 memory Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000004112 neuroprotection Effects 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 230000002633 protecting effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 235000008160 pyridoxine Nutrition 0.000 description 2
- 239000011677 pyridoxine Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000005932 reductive alkylation reaction Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 208000022925 sleep disturbance Diseases 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- DKXIKPOYTWCGIE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-methylbutanoate Chemical compound CCC(C)C(=O)ON1C(=O)CCC1=O DKXIKPOYTWCGIE-UHFFFAOYSA-N 0.000 description 1
- FHNMAOLQZHUPIJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-methylpropanoate Chemical compound CC(C)C(=O)ON1C(=O)CCC1=O FHNMAOLQZHUPIJ-UHFFFAOYSA-N 0.000 description 1
- DYMYLBQTHCJHOQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) butanoate Chemical compound CCCC(=O)ON1C(=O)CCC1=O DYMYLBQTHCJHOQ-UHFFFAOYSA-N 0.000 description 1
- ZJIFDEVVTPEXDL-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) hydrogen carbonate Chemical compound OC(=O)ON1C(=O)CCC1=O ZJIFDEVVTPEXDL-UHFFFAOYSA-N 0.000 description 1
- DRLIANXPAARUMI-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) pentanoate Chemical compound CCCCC(=O)ON1C(=O)CCC1=O DRLIANXPAARUMI-UHFFFAOYSA-N 0.000 description 1
- AASBXERNXVFUEJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) propanoate Chemical compound CCC(=O)ON1C(=O)CCC1=O AASBXERNXVFUEJ-UHFFFAOYSA-N 0.000 description 1
- QHSCIWIRXWFIGH-LURJTMIESA-N (2s)-2-amino-2-methylpentanedioic acid Chemical compound OC(=O)[C@](N)(C)CCC(O)=O QHSCIWIRXWFIGH-LURJTMIESA-N 0.000 description 1
- HTFFMYRVHHNNBE-YFKPBYRVSA-N (2s)-2-amino-6-azidohexanoic acid Chemical compound OC(=O)[C@@H](N)CCCCN=[N+]=[N-] HTFFMYRVHHNNBE-YFKPBYRVSA-N 0.000 description 1
- PKMOKWXRSKRYMX-UHFFFAOYSA-N 2-azanyl-2-methyl-propanoic acid Chemical compound CC(C)(N)C(O)=O.CC(C)(N)C(O)=O PKMOKWXRSKRYMX-UHFFFAOYSA-N 0.000 description 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 101150053137 AIF1 gene Proteins 0.000 description 1
- 101150037123 APOE gene Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000012619 Butyl Sepharose® Substances 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 1
- 241001573498 Compacta Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 206010012239 Delusion Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 206010014513 Embolism arterial Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000036187 Genetic neurodegenerative disease Diseases 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 1
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000012412 Presenilin-1 Human genes 0.000 description 1
- 108010036933 Presenilin-1 Proteins 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 241001323319 Psen Species 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 208000013404 behavioral symptom Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 210000005257 cortical tissue Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 231100000868 delusion Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000006739 dopaminergic cell death Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000001353 entorhinal cortex Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 231100000318 excitotoxic Toxicity 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000006126 farnesylation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000030135 gastric motility Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 101150113725 hd gene Proteins 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000006951 hyperphosphorylation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000008798 inflammatory stress Effects 0.000 description 1
- 208000030309 inherited neurodegenerative disease Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000007326 intracellular aggregation Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004558 lewy body Anatomy 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000019988 mead Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000006724 microglial activation Effects 0.000 description 1
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000000478 neocortex Anatomy 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 230000002314 neuroinflammatory effect Effects 0.000 description 1
- 230000007514 neuronal growth Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 210000001152 parietal lobe Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000007161 peripheral neurotransmission Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 108010040003 polyglutamine Proteins 0.000 description 1
- 229920000155 polyglutamine Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- the present invention relates to the therapeutic use of a triple activator and/or a conjugate thereof having activity on both glucagon, GLP-1 and GIP receptors for neurodegenerative diseases.
- Neurodegenerative diseases are diseases that include all conditions in which nerve cells degenerate.
- Parkinson's disease a type of neurodegenerative disease, leads to selective degeneration of neurons, usually nigrostriatal, in which the ability to synthesize dopamine is greatly reduced and, as a result, fails to connect to striatal dopamine receptors.
- It is a chronic neurodegenerative disease of muscle movement, characterized by Prior to clinical manifestation of disease, apoptosis occurs silently in the substantianigra pars compacta (SNc), presumably a simultaneous apoptotic, excitotoxic, free-radical mediated neuroinflammatory event. It is known to be the result of A therapeutic strategy that provides a cure for the pathology of PD, or a means to brake the pathology of PD, remains elusive.
- Established drug treatment regimens are essentially temporary regimens and are not effective for all patients. Since apoptotic cell death is one of the central components in selective substantia nigra neuron death, future therapeutic strategies may include the targeted use of bio-molecules with anti-apoptotic properties. Alternatively, a positive therapeutic effect can be produced by molecules with neurotrophic properties or the ability to stimulate neurogenesis in cells with a dopaminergic phenotype.
- Huntington's disease a disease mixed with Huntington's chorea, is a genetic neurodegenerative disease typified by mental and cognitive abnormalities as well as involuntary physical movements.
- a genetic defect based on HD involves an expansion of the CAG trinucleotide repeat in exon 1 of the HD gene, which results in a polyglutamine expansion in the huntingtin (htt) protein. This leads to aberrant processing and deleterious intracellular aggregation.
- AD Alzheimer's disease
- cortical neurons particularly associative neocortex and hippocampus
- a key feature of this disease is the aggregation and deposition of misfolded proteins: (1) aggregated beta-amyloid (A ⁇ ) peptides as extracellular senile or neurogenic 'plaques', and (2) intracellular nerve fibers'
- a ⁇ aggregated beta-amyloid
- NFT neurofibrillary tangle
- AD Alzheimer's disease
- APP amyloid precursor protein
- PSEN 1 presenilin 1
- PSEN2 presenilin 2
- FDA US Food and Drug Administration
- AD Alzheimer's disease
- acetylcholinesterase inhibitors such as Donepizil, Rivastigmine, Galantamine and the NMDA receptor antagonist memantine.
- statins cholesterol level reducing agents
- antihypertensive drugs or anti-inflammatory drugs. None of these drugs have been shown to reduce the progression of AD. Accordingly, other strategies for treating AD are underway.
- neuronal growth factor ⁇ NNF
- exendin-4 reduced brain damage and improved functional outcome in a mouse model of transient middle cerebral artery occlusion stroke (Proc Natl Acad Sci US A. 2009 Jan 27;106(4):1285). -90).
- GLP-1 receptor stimulation with exendin-4 attenuated ischemia-related neuronal death by interfering with microglial activation against transient brain ischemia injury (J. Neurosci Res. 2011 Jul;89(7):1103-13).
- exendin-4 was effective in a mouse model of brain ischemia-perfusion injury. Exendin-4 treatment significantly reduced infarct volume and improved functional deficits.
- One object of the present invention is a glucagon receptor, GLP-1 (Glucagon-like peptide-1) receptor, and a peptide having activity on the GIP (glucose-dependent insulinotropic polypeptide) receptor, or a neuron comprising a long-acting conjugate of such a peptide
- GLP-1 Glucagon-like peptide-1
- GIP glycose-dependent insulinotropic polypeptide
- Another object of the present invention is the peptide or a long-acting conjugate of such a peptide; Or to provide a method for preventing or treating a neurodegenerative disease, comprising administering a composition comprising the peptide or the long-acting conjugate to an individual in need thereof.
- Another object of the present invention is in the preparation of a medicament for the prevention or treatment of neurodegenerative diseases, the peptide or a long-acting conjugate of the peptide; Or to provide the use of a composition comprising the peptide or the long-acting conjugate.
- Another object of the present invention is to provide a composition for protecting dopaminergic cells comprising the peptide or a long-acting conjugate of the peptide.
- the triple activator or long-acting conjugate thereof according to the present invention has activity on glucagon receptor, GLP-1 receptor, and GIP receptor, thereby expanding the category of drugs applicable to neurodegenerative diseases to date, thereby broadening the options of patients. And by remarkably increasing the blood half-life, it is possible to increase the convenience of patients.
- FIG. 1 is a diagram showing the results of changes in the behavior (rotarod) of mice 7 days after administration of a long-acting triple activator conjugate in a mouse model of acute Parkinson's disease induced by MPTP. (*p ⁇ 0.05, **p ⁇ 0.01, ***p ⁇ 0.001, vs. excipient control by One-way ANOVA).
- Figure 2 shows the number of dopaminergic cells according to the progression of Parkinson's disease in the substantia nigra after the administration of the long-acting triple activator conjugate in a mouse model of MPTP-induced acute Parkinson's disease, and 7 days after the brain tissue extraction of the mouse.
- a diagram showing the results of measuring the inhibitory activity of the triple activator conjugate for reduction (*p ⁇ 0.05, **p ⁇ 0.01, ***p ⁇ 0.001, vs. excipient control by One-way ANOVA).
- FIG. 3 is a diagram showing the results of changes in the area occupied by microglia in the striatum after administration of a long-acting triple activator conjugate in a mouse model of chronic Parkinson's disease induced by MPTP/probenecid (*p ⁇ 0.05, **p ⁇ 0.01, ***p ⁇ 0.001, vs. excipient control by One-way ANOVA).
- FIG. 4 is a diagram showing the results of changes in the amount of alpha-synuclein expression in the striatum after administration of a long-acting triple activator conjugate in a mouse model of chronic Parkinson's disease induced by MPTP/probenecid (*p ⁇ 0.05, **p ⁇ 0.01) , ***p ⁇ 0.001, vs. excipient control by One-way ANOVA).
- amyloid beta 1-42 protein known as a causative agent of Alzheimer's disease
- a long-acting triple activator conjugate in a mouse model of Alzheimer's disease (*p ⁇ 0.05, **p ⁇ 0.01, ***p ⁇ 0.001, vs. excipient control by One-way ANOVA).
- FIG. 6 is a diagram showing the results of changes in the final glycation end products (AGE) in the cerebral cortex after administration of the long-acting triple activator conjugate in a mouse model of Alzheimer's disease (*p ⁇ 0.05, **p ⁇ 0.01, ***p ⁇ 0.001, vs. excipient control by One-way ANOVA).
- FIG. 7 is a diagram illustrating the anti-inflammatory effect after administration of a long-acting triple activator conjugate in a mouse model of Alzheimer's disease through the results of changes in interleukin-1 beta, an inflammatory cytokine in the cerebral cortex (*p ⁇ 0.05, **p ⁇ 0.01, ***p ⁇ 0.001, vs. excipient control by One-way ANOVA).
- FIG. 8 is a diagram confirming the protective effect on oxidative stress after administration of the long-acting triple activator conjugate in a mouse model of Alzheimer's disease through the change result of the HNE (4-hydroxynoenal)-protein conjugate in the cerebral cortex (*p ⁇ 0.05, **p ⁇ 0.01, ***p ⁇ 0.001, vs. excipient control by One-way ANOVA).
- One aspect embodying the present invention is a glucagon receptor, GLP-1 (Glucagon-like peptide-1) receptor, and GIP (Glucose-dependent insulinotropic polypeptide) prevention or neurodegenerative disease comprising a peptide having activity on the receptor It is a pharmaceutical composition for treatment.
- GLP-1 Glucagon-like peptide-1
- GIP Glucose-dependent insulinotropic polypeptide
- the pharmaceutical composition for the prevention or treatment of the neurodegenerative disease comprises a pharmaceutically effective amount of a pharmaceutically acceptable excipient and a peptide comprising the amino acid sequence of any one of SEQ ID NOs: 1 to 102 characterized in that
- composition according to any one of the preceding embodiments, wherein the peptide is in the form of a long-acting conjugate, and the long-acting conjugate is characterized in that it is represented by the following formula (1):
- X is a peptide of any one of SEQ ID NOs: 1 to 102;
- L is a linker containing an ethylene glycol repeating unit
- F is an immunoglobulin Fc region
- composition according to any one of the preceding embodiments, wherein the peptide is amidated at its C-terminus.
- composition according to any one of the preceding embodiments, wherein the peptide has an amidated C-terminus or a free carboxyl group (-COOH).
- composition according to any one of the preceding embodiments, wherein the peptide is selected from the group consisting of SEQ ID NOs: 21, 22, 42, 43, 50, 64, 66, 67, 70, 71, 76, 77, 96, 97 and 100 It is characterized in that it contains amino acids.
- composition according to any one of the preceding embodiments, wherein the peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 21, 22, 42, 43, 50, 77 and 96.
- composition according to any one of the preceding embodiments, wherein the peptide sequence is characterized in that amino acids 16 and 20 from the N-terminus form a ring with each other.
- composition according to any one of the preceding embodiments, wherein L is polyethylene glycol.
- composition according to any one of the preceding embodiments, wherein F is an IgG Fc region.
- composition according to any one of the preceding embodiments, wherein the immunoglobulin Fc region is non-glycosylated.
- the immunoglobulin Fc region comprises (a) a CH1 domain, a CH2 domain, a CH3 domain and a CH4 domain; (b) a CH1 domain and a CH2 domain; (c) a CH1 domain and a CH3 domain; (d) a CH2 domain and a CH3 domain; (e) a combination of one or more domains of a CH1 domain, a CH2 domain, a CH3 domain and a CH4 domain with an immunoglobulin hinge region or portion of a hinge region; And (f) it is characterized in that it is selected from the group consisting of a dimer of each domain of the heavy chain constant region and the light chain constant region.
- composition according to any one of the preceding embodiments, wherein, in the immunoglobulin Fc region, a site capable of forming a disulfide bond is removed, some amino acids at the N-terminus of the native Fc are removed, or the N-terminus of the native Fc It is characterized in that a methionine residue is added, a complement binding site is removed, or an antibody dependent cell mediated cytotoxicity (ADCC) site is removed.
- ADCC antibody dependent cell mediated cytotoxicity
- composition according to any one of the preceding embodiments, wherein the immunoglobulin Fc region is derived from IgG, IgA, IgD, IgE or IgM.
- composition according to any one of the preceding embodiments, wherein the immunoglobulin Fc region is a hybrid of domains having different origins derived from an immunoglobulin selected from the group consisting of IgG, IgA, IgD, IgE, and IgM.
- composition according to any one of the preceding embodiments, wherein the immunoglobulin Fc region is in a dimeric form.
- composition according to any one of the preceding embodiments, wherein the immunoglobulin Fc region is an IgG4 Fc region.
- composition according to any one of the preceding embodiments, wherein the immunoglobulin Fc region is a non-glycosylated Fc region derived from human IgG4.
- composition according to any one of the preceding embodiments characterized in that F and X, which are the immunoglobulin Fc regions, are not glycosylated.
- the conjugate is a covalent bond formed by reacting one end of L with an amine group or thiol group of F, and the other end of L with an amine group or thiol group of X, respectively, to F and X
- F and X Each is characterized in that it is connected.
- composition according to any one of the preceding embodiments, wherein L is polyethylene glycol.
- the neurodegenerative disease is Parkinson's disease, Huntington's disease, Alzheimer's disease, progressive supranuclear palsy (PSP), multiple system atrophy (MSA), Lewy body dementia ( It is characterized in that it is at least one disease selected from the group consisting of Lewy body dementia), Parkinson's disease dementia, epilepsy, stroke, cerebral hypoxia, peripheral neuropathy, and nerve damage due to side effects of diabetes.
- composition according to any one of the preceding embodiments, wherein the neurodegenerative disease is Alzheimer's disease.
- composition according to any one of the preceding embodiments, wherein the neurodegenerative disease is Parkinson's disease or stroke.
- composition according to any one of the preceding embodiments, wherein the pharmaceutical composition has one or more of the following properties:
- composition according to any one of the preceding embodiments, wherein the pharmaceutical composition has one or more of the following properties:
- Another aspect for implementing the present invention is the peptide or a long-acting conjugate of such a peptide; Or, it is a method for preventing or treating neurodegenerative diseases, comprising administering a composition comprising the peptide or the long-acting conjugate to an individual in need thereof.
- Another aspect for implementing the present invention is the peptide or a long-acting conjugate of such a peptide in the preparation of a medicament for the prevention or treatment of neurodegenerative diseases; or the use of a composition comprising the peptide or the long-acting conjugate.
- Another aspect for implementing the present invention is the peptide or a long-acting conjugate of the peptide for the prevention or treatment of neurodegenerative diseases; or the use of a composition comprising the peptide or the long-acting conjugate.
- Another aspect embodying the present invention is the peptide or a long-acting conjugate of such a peptide; or the use of a composition comprising the peptide or the long-acting conjugate to protect dopaminergic cells.
- Another aspect embodying the present invention is a composition for cell protection of the peptide or a composition comprising a long-acting conjugate of the peptide.
- Aib may be used interchangeably with “2-aminoisobutyric acid” or “aminoisobutyric acid”, and 2-aminoisobutyric acid and aminoiso Butyric acid (aminoisobutyric acid) may be used in combination.
- One aspect for implementing the present invention is a glucagon receptor, GLP-1 (Glucagon-like peptide-1) receptor, and GIP (Glucose-dependent insulinotropic polypeptide) having activity on the receptor, including a peptide, neurodegenerative disease is a pharmaceutical composition for the prevention or treatment of
- the peptide may include the amino acid sequence of any one of SEQ ID NOs: 1 to 102.
- the pharmaceutical composition for the prevention or treatment of the neurodegenerative disease comprises a pharmaceutically effective amount of a pharmaceutically acceptable excipient and a peptide comprising the amino acid sequence of any one of SEQ ID NOs: 1 to 102 It may be a pharmaceutical composition
- composition of the present invention may include a glucagon receptor, a GLP-1 receptor, and a peptide having activity on the GIP receptor in a pharmacologically effective amount, specifically, any one of the amino acid sequences of SEQ ID NOs: 1 to 102 It may include, but is not limited to, a pharmacologically effective amount of a peptide (triple active substance) comprising, consisting essentially of, or consisting of.
- peptide having activity against glucagon receptor, GLP-1 receptor, and GIP receptor may be used interchangeably as the term “triple activator” or “triple activator peptide” in the present invention.
- the triple activator of the present invention may include a peptide comprising any one of the amino acid sequences of SEQ ID NOs: 1 to 102.
- a peptide consisting essentially of or consisting of any one of the amino acid sequences of SEQ ID NOs: 1 to 102 may also be included in the triple activator of the present invention, but is not limited thereto.
- the peptide comprising the amino acid sequence of any one of SEQ ID NOs: 1 to 102 is an example of a peptide having activity against a glucagon receptor, a GLP-1 receptor, and a GIP receptor, but is not limited thereto.
- Such peptides include various substances with significant levels of activity on glucagon, GLP-1, and GIP receptors, such as various peptides.
- the triple activator having a significant level of activity on the glucagon, GLP-1, and GIP receptors includes one or more receptors of glucagon, GLP-1, and GIP receptors, specifically two or more More specifically, the in vitro activity for all three receptors is about 0.001% or more, about 0.01% or more, compared to the native ligand (natural glucagon, native GLP-1, and native GIP) of the corresponding receptor; about 0.1% or more, about 1% or more, about 2% or more, about 3% or more, about 4% or more, about 5% or more, about 6% or more, about 7% or more, about 8% or more, about 9% or more, about 10% or more, about 20% or more, about 30% or more, about 40% or more, about 50% or more, about 60% or more, about 70% or more, about 80% or more, about 90% or more, about 100% or more, It may represent about 150% or more, about 200% or more, but a range of significantly increased is included without
- the activity on the receptor is about 0.001% or more, 0.01% or more, 0.1% or more, 1% or more, 2% or more, 3% or more, 4% or more, 5% or more, the in vitro activity of the receptor compared to the native type. , 6% or more, 7% or more, 8% or more, 9% or more, 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90 % or more, 100% or more, or about 200% or more may be exemplified. However, the present invention is not limited thereto.
- the term “about” includes all values within a range including ⁇ 0.5, ⁇ 0.4, ⁇ 0.3, ⁇ 0.2, ⁇ 0.1, etc., and includes all values in a range equal to or similar to the value following the term about, but not limited
- the peptide is characterized in that it possesses one or more, two or more, specifically three activities of the following i) to iii), specifically, it possesses a significant activity:
- activating the receptor means that the in vitro activity of the receptor compared to the native type is about 0.001% or more, about 0.01% or more, about 0.1% or more, about 1% or more, about 2% or more, about 3% or more, about 4 % or more, about 5% or more, about 6% or more, about 7% or more, about 8% or more, about 9% or more, about 10% or more, about 20% or more, about 30% or more, about 40% or more, about 50 % or more, about 60% or more, about 70% or more, about 80% or more, about 90% or more, about 100% or more, about 150% or more, about 200% or more.
- the present invention is not limited thereto.
- the peptide may have an increased half-life in the body compared to any one of native GLP-1, native glucagon, and native GIP, but is not particularly limited thereto.
- the peptide may be non-naturally occurring.
- a peptide of the invention comprises, (essentially) consists of, or (essentially) the amino acid sequence of any one of SEQ ID NOs: 1-102, or any one of SEQ ID NOs: 1-102. Any one amino acid sequence and at least 60% or more, 65% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more , or may also include a peptide having more than 95% sequence identity, and as long as it has a therapeutic and/or preventive effect on neurodegenerative diseases, it is not limited to a specific sequence.
- triple activator examples include those comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 102, SEQ ID NOs: 1 to 11, those comprising an amino acid sequence selected from the group consisting of 13 to 102, SEQ ID NOs: It may be (essentially) composed of an amino acid sequence selected from the group consisting of 1 to 11, 13 to 102, but is not limited thereto.
- the triple active peptide is SEQ ID NO: 21 to 24, 28, 29, 31, 32, 37, 42, 43, 50, 51 to 54, 56, 58, 64 to 73, 75 to 79 , 82, 83, 91, and may include, consist essentially of, or consist of the amino acid sequence of any one of 96 to 102, but is not limited thereto.
- the triple activator peptide comprises the amino acid sequence of any one of SEQ ID NOs: 21, 22, 42, 43, 50, 64, 66, 67, 70, 71, 76, 77, 96, 97 and 100, It may consist essentially of, or may be configured, but is not limited thereto.
- the peptide comprises, consists essentially of, or consists of any one amino acid sequence of SEQ ID NOs: 21, 22, 42, 43, 50, 66, 67, 77, 96, 97 and 100 can, but is not limited thereto.
- the peptide may include, consist essentially of, or consist of any one amino acid sequence of SEQ ID NOs: 21, 22, 42, 43, 50, 77 and 96, but is not limited thereto.
- the term 'homology' or 'identity' refers to the degree to which two given amino acid sequences or nucleotide sequences are related to each other and may be expressed as a percentage.
- Whether any two peptide sequences have homology, similarity or identity can be determined, for example, by Pearson et al (1988) [Proc. Natl. Acad. Sci. USA 85]: 2444, using a known computer algorithm such as the “FASTA” program. or, as performed in the Needleman program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet. 16: 276-277) (version 5.0.0 or later), The Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453) can be used to determine.
- GAP program is defined as the total number of symbols in the shorter of two sequences divided by the number of similarly aligned symbols (ie, amino acids).
- Default parameters for the GAP program are: (1) a binary comparison matrix (containing values of 1 for identity and 0 for non-identity) and Schwartz and Dayhoff, eds., Atlas Of Protein Sequence And Structure, National Biomedical Research Foundation, pp.
- the peptide having activity on the glucagon receptor, the GLP-1 receptor, and the GIP receptor may include an intramolecular bridge (eg, a covalent bridge or a non-covalent bridge), specifically a ring It may be in a form containing, for example, a ring formed between amino acids 16 and 20 of the peptide, but is not particularly limited thereto.
- an intramolecular bridge eg, a covalent bridge or a non-covalent bridge
- a ring may be in a form containing, for example, a ring formed between amino acids 16 and 20 of the peptide, but is not particularly limited thereto.
- Non-limiting examples of the ring may include a lactam bridge (or lactam ring).
- the peptide includes all those modified to include a ring and an amino acid capable of forming a ring at a desired position.
- the pair of amino acids 16 and 20 of the peptide may be substituted with glutamic acid or lysine, each capable of forming a ring, but is not limited thereto.
- Such a ring may be formed between amino acid side chains in the peptide, for example, a lactam ring may be formed between a lysine side chain and a glutamic acid side chain, but is not particularly limited thereto.
- one or more amino acid sequences are different from those of native glucagon, and the alpha-carbon of the amino acid residue at the N-terminus has been removed, glucagon receptor, GLP-1 receptor, and activity against GIP receptor
- amino acids may be substituted with other amino acids or non-natural compounds in order to avoid the recognition action of an activator degrading enzyme in order to increase the half-life in the body.
- the peptide may be a peptide having an increased half-life in the body by avoiding the recognition action of the degrading enzyme through substitution of the second amino acid sequence among the amino acid sequence of the peptide, but amino acid substitution or alteration to avoid the recognition action of the degrading enzyme in the body included without limitation.
- modifications for the production of peptides include modifications with L- or D-form amino acids, and/or non-natural amino acids; and/or by modifying the native sequence, e.g., modification of side chain functional groups, intramolecular covalent bonds, such as inter-side chain ring formation, methylation, acylation, ubiquitination, phosphorylation, aminohexylation, biotinylation, etc. includes all that
- amino acids to be substituted or added may be atypical or non-naturally occurring amino acids as well as the 20 amino acids commonly observed in human proteins.
- Commercial sources of atypical amino acids include Sigma-Aldrich, ChemPep and Genzyme Pharmaceuticals. Peptides containing these amino acids and canonical peptide sequences can be synthesized and purchased from commercial peptide synthesis companies, for example, American peptide company or Bachem in the United States, or Anygen in Korea.
- Amino acid derivatives can also be obtained in the same manner, and 4-imidazoacetic acid can be used, to name just a few examples.
- the peptide according to the present invention has its N-terminus and/or C-terminus chemically modified or protected by an organic group in order to protect it from proteolytic enzymes in vivo and to increase stability, or amino acids are added to the peptide terminus, etc. It may be in a modified form by adding it.
- the N-terminus is acetylated and/or the C-terminus is amidated to remove these charges.
- it is not particularly limited thereto.
- the N-terminus or C-terminus of the peptide of the present invention may have an amine group (-NH2) or a carboxyl group (-COOH), but is not limited thereto.
- the C-terminus of the peptide according to the present invention may be an amidated peptide or a peptide having a free carboxyl group (-COOH), or may include a peptide having an unmodified C-terminus, but is not limited thereto.
- the peptide may have an amidated C-terminus, but is not limited thereto.
- the peptide may be non-glycosylated, but is not limited thereto.
- the peptide of the present invention can be synthesized through a solid phase synthesis method, can also be produced by a recombinant method, and can be produced by requesting commercially, but is not limited thereto.
- the length of the peptide of the present invention can be synthesized by a method well known in the art, for example, an automatic peptide synthesizer, or it can be produced by a genetic engineering technique.
- the peptides of the present invention can be prepared by standard synthetic methods, recombinant expression systems, or any other method in the art.
- the peptides according to the invention can be synthesized in a number of ways, including, for example, those comprising:
- a method for obtaining a fragment of a peptide by any combination of (a), (b) and (c), and then ligating the fragments to obtain a peptide, and recovering the peptide.
- the peptide having activity on the glucagon receptor, GLP-1 receptor, and GIP receptor is biocompatibility for increasing the in vivo half-life of the peptide having activity on the glucagon receptor, GLP-1 receptor, and GIP receptor.
- the substance may be in the form of a bound, long-acting binder.
- the biocompatible material may be mixed with a carrier.
- the peptide included in the pharmaceutical composition of the present invention may be in the form of a long-acting conjugate.
- the peptide conjugate may exhibit increased potency and durability compared to the peptide to which a carrier is not bound, and in the present invention, such a conjugate is referred to as a "persistent conjugate".
- the long-acting conjugate refers to a form in which an immunoglobulin Fc region is linked to a peptide having activity against a glucagon receptor, a GLP-1 receptor, and a GIP receptor.
- the conjugate may be a glucagon receptor, a GLP-1 receptor, and an immunoglobulin Fc region covalently linked to a peptide having activity on the GIP receptor through a linker, but is not particularly limited thereto.
- the long-acting binder may be one represented by the following formula (1), but is not limited thereto:
- X is a peptide comprising the amino acid sequence of any one of SEQ ID NOs: 1 to 102;
- L is a linker containing ethylene glycol repeating units
- F is an immunoglobulin Fc region
- the term "long-acting conjugate of Formula 1" refers to a form in which a peptide comprising the amino acid sequence of any one of SEQ ID NOs: 1 to 102 and an immunoglobulin Fc region are linked to each other by a linker, wherein the conjugate is an immunoglobulin Fc region binding It may exhibit increased potency persistence compared to a peptide comprising the amino acid sequence of any one of SEQ ID NOs: 1 to 102, which is not.
- the conjugate of the present invention can exhibit significant activity on the glucagon receptor, the GLP-1 receptor, and the GIP receptor even in the form of the conjugate, and thus can also exert a preventive and/or therapeutic effect on neurodegenerative diseases.
- the conjugate of the present invention has an in vitro activity of about 0.01% or more, 0.1% or more, 0.2% or more, 0.5% or more, 0.7% or more for glucagon receptor, GLP-1 receptor, and/or GIP receptor compared to the native type. , 1% or more, 2% or more, 3% or more, 4% or more, 5% or more, 6% or more, 7% or more, 8% or more, 9% or more, 10% or more, 20% or more, 30% or more, 40 % or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, 100% or more, but is not limited thereto.
- the peptide or its conjugate has an activity of about 0.01% or more, 0.1% or more, 1% or more, 2% or more, 3 or more for the glucagon receptor, GLP-1 receptor, and/or GIP receptor compared to the native type. % or more, 4% or more, 5% or more, 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, 100% or more may be, but is not limited thereto.
- composition of the present invention comprises (i) a peptide having activity on the glucagon receptor, the GLP-1 receptor, and the GIP receptor, or (ii) the peptide having activity on the glucagon receptor, the GLP-1 receptor, and the GIP receptor. It may include a type conjugate, and the long-acting conjugate may exhibit an excellent preventive and/or therapeutic effect on neurodegenerative diseases based on increased persistence in the body.
- F is X, that is, a peptide having activity against a glucagon receptor, a GLP-1 receptor, and a GIP receptor, specifically, the half-life of a peptide comprising any one of the amino acid sequences of SEQ ID NOs: 1 to 102 As a substance capable of increasing, it corresponds to one component of the moiety constituting the conjugate of the present invention.
- the F may be bonded to each other by a covalent chemical bond or a non-covalent chemical bond with X, and F and X may be connected to each other through a linker (L) by a covalent chemical bond, a non-covalent chemical bond, or a combination thereof.
- the conjugate may be one in which X and L, and L and F are connected to each other by a covalent bond.
- the method of linking X which is a peptide comprising the amino acid sequence of any one of SEQ ID NOs: 1 to 102 of the long-acting conjugate of Formula 1, and the immunoglobulin Fc region is not particularly limited, but among SEQ ID NOs: 1 to 102 through a linker A peptide comprising any one amino acid sequence and an immunoglobulin Fc region may be linked to each other.
- L may be a non-peptidyl linker, for example, a linker containing an ethylene glycol repeating unit.
- non-peptidyl linker includes a biocompatible polymer in which two or more repeating units are bonded. The repeating units are linked to each other through any covalent bond other than a peptide bond.
- the non-peptidyl linker may be one component constituting a moiety of the conjugate of the present invention, and corresponds to L in Formula 1 above.
- the non-peptidyl linker that can be used in the present invention may be used without limitation as long as it is a polymer resistant to proteolytic enzymes in vivo.
- the non-peptidyl linker may be used in combination with a non-peptidyl polymer.
- the non-peptidyl linker may include a reactive group at the end thereof to form a conjugate through reaction with other components constituting the conjugate.
- a non-peptide linker having reactive functional groups at both ends binds with X and F of Formula 1 through each reactive group to form a conjugate
- the non-peptide linker or non-peptide polymer is a non-peptide polymer linker (linker). moiety) or a non-peptidyl linker linkage.
- non-peptidyl linker may be a linker containing an ethylene glycol repeating unit, for example, a polyethylene glycol linker, and also derivatives thereof known in the art and easy at the level of skill in the art. Derivatives that can be easily prepared are also included in the scope of the present invention.
- polyethylene glycol linker includes a biocompatible polymer in which two or more ethylene glycol repeating units are bonded. The repeating units are linked to each other through any covalent bond other than a peptide bond.
- the polyethylene glycol linker may be one component constituting the moiety of the conjugate of the present invention, and corresponds to L in Formula 1 above.
- L may be a linker containing an ethylene glycol repeating unit, for example, polyethylene glycol, but is not limited thereto.
- the polyethylene glycol is a term encompassing all forms of ethylene glycol homopolymer, PEG copolymer, or monomethyl-substituted PEG polymer (mPEG), but is not particularly limited thereto.
- mPEG monomethyl-substituted PEG polymer
- derivatives thereof known in the art and derivatives that can be easily prepared at the level of skill in the art are also included in the scope of the present invention.
- the polyethylene glycol linker may include an ethylene glycol repeating unit and a functional group used in the preparation of the conjugate at the terminal before being formed into a conjugate.
- the long-acting conjugate according to the present invention may be in a form in which X and F are linked through the functional group, but is not limited thereto.
- the non-peptidyl linker may include two, or three or more functional groups, and each functional group may be the same or different from each other, but is not limited thereto.
- the linker may be polyethylene glycol (PEG) represented by the following formula (2), but is not limited thereto:
- the PEG moiety in the long-acting conjugate may include, but is not limited to, the -(CH2CH2O)n- structure as well as an oxygen atom intervening between the linking element and the -(CH2CH2O)n-.
- the ethylene glycol repeating unit may be represented by, for example, [OCH 2 CH 2 ]n, and the value of n is a natural number, the average molecular weight of the [OCH 2 CH 2 ]n site in the peptide conjugate, such as The number average molecular weight may be set to be greater than 0 to about 100 kDa, but is not limited thereto.
- the n value is a natural number
- the average molecular weight of the [OCH 2 CH 2 ]n site in the peptide conjugate for example, has a number average molecular weight of about 1 to about 100 kDa, about 1 to about 80 kDa, about 1 to about 50 kDa, about 1 to about 30 kDa, about 1 to about 25 kDa, about 1 to about 20 kDa, about 1 to about 15 kDa, about 1 to about 13 kDa, about 1 to about 11 kDa, about 1 to about 10 kDa, about 1 to about 8 kDa, about 1 to about 5 kDa, about 1 to about 3.4 kDa, about 3 to about 30 kDa, about 3 to about 27 kDa, about 3 to about 25 kDa, about 3 to about 22 kDa , about 3 to about 20 kDa, about 3 to about 18 kDa, about 3 to about 16 kDa
- the conjugate may have a structure in which the peptide (X) and the immunoglobulin Fc region (F) are covalently linked through a linker containing an ethylene glycol repeating unit, but is not limited thereto.
- the long-acting conjugate may have a structure in which the peptide (X) of the present invention and the immunoglobulin Fc region (F) are covalently linked through a linker (L) containing an ethylene glycol repeating unit. , but is not limited thereto.
- the non-peptidyl linker that can be used in the present invention may be used without limitation as long as it is a polymer including an ethylene glycol repeating unit resistant to proteolytic enzymes in vivo.
- the molecular weight of the non-peptidyl polymer is, but is not limited to, greater than 0, in the range of about 100 kDa, in the range of about 1 to about 100 kDa, specifically in the range of about 1 to about 20 kDa, or in the range of about 1 to about 10 kDa.
- the non-peptidyl linker of the present invention coupled to the polypeptide corresponding to F not only one type of polymer but also a combination of different types of polymers may be used.
- both ends of the non-peptidyl linker are each F, such as a thiol group, an amino group, a hydroxyl group of an immunoglobulin Fc region, and a thiol group, an amino group, an azide group or a hydroxyl group of the peptide (X). may be coupled to, but is not limited thereto.
- F such as a thiol group, an amino group, a hydroxyl group of an immunoglobulin Fc region, and a thiol group, an amino group, an azide group or a hydroxyl group of the peptide (X).
- the linker comprises a reactive group capable of binding to F (eg, immunoglobulin Fc region) and X, respectively, at both ends, specifically, a thiol group of a cysteine of an immunoglobulin Fc region; an amino group located at the N-terminus, lysine, arginine, glutamine and/or histidine; and/or a thiol group of a cysteine of peptide (X) bonded to a hydroxyl group located at the C-terminus; amino groups of lysine, arginine, glutamine and/or histidine; azide group of azidolysin; and/or a reactive group capable of bonding to a hydroxyl group, but is not limited thereto.
- F immunoglobulin Fc region
- X thiol group of a cysteine of an immunoglobulin Fc region
- the reactive group of the linker capable of binding to F such as an immunoglobulin Fc region and X, may be selected from the group consisting of an aldehyde group, a maleimide group and a succinimide derivative, but is not limited thereto.
- the aldehyde group may be exemplified by a propionaldehyde group or a butyl aldehyde group, but is not limited thereto.
- succinimidyl valerate succinimidyl methylbutanoate, succinimidyl methylpropionate, succinimidyl butanoate, succinimidyl propionate, N-hydroxysuccini Mead, hydroxy succinimidyl, succinimidyl carboxymethyl or succinimidyl carbonate may be used, but are not limited thereto.
- the linker may be connected to F, which is an immunoglobulin Fc region, and X, which is a peptide (triple activator) through the same reactive group as described above, and may be converted into a linker linkage.
- the final product resulting from reductive amination by aldehyde bonds is much more stable than those linked by amide bonds.
- the aldehyde reactive group selectively reacts with the N-terminus at a low pH, and can form a covalent bond with a lysine residue at a high pH, for example, pH 9.0.
- the reactive groups at both ends of the non-peptidyl linker may be the same or different from each other, for example, a maleimide group at one end and an aldehyde group, a propionaldehyde group, or a butyl aldehyde group at the other end.
- F specifically, an immunoglobulin Fc region and X can be bound to each end of the non-peptidyl linker, it is not particularly limited thereto.
- one end of the non-peptidyl linker may include a maleimide group as a reactive group, and an aldehyde group, a propionaldehyde group, or a butyl aldehyde group at the other end of the non-peptidyl linker.
- the hydroxyl group can be activated into the various reactive groups by a known chemical reaction, or a commercially available polyethylene glycol having a modified reactive group is used.
- the long-acting protein conjugate of the invention can be prepared.
- the non-peptidyl polymer may be linked to a cysteine residue of X, more specifically, a -SH group of cysteine, but is not limited thereto.
- cysteine residue 10 cysteine 13, cysteine 15, cysteine 17, cysteine 19, cysteine 21, cysteine 24, cysteine 28, 29
- the non-peptidyl polymer may be linked to cysteine residue No. 30, cysteine residue 30, cysteine 31, cysteine 40, or cysteine 41, but is not particularly limited thereto.
- a reactive group of the non-peptidyl polymer may be linked to the -SH group of the cysteine residue, and all of the above descriptions apply to the reactive group.
- maleimide-PEG-aldehyde is used, the maleimide group is connected to the -SH group of X by a thioether bond, and the aldehyde group is F, specifically, the -NH 2 group of immunoglobulin Fc by reductive amination reaction may be connected through, but is not limited thereto, and this corresponds to one example.
- the reactive group of the non-peptidyl polymer may be linked to -NH 2 located at the N-terminus of the immunoglobulin Fc region, but this corresponds to one example.
- maleimide-PEG-aldehyde is used, the maleimide group is linked to the -SH group of the peptide by a thioether bond, and the aldehyde group can be linked to the -NH 2 group of immunoglobulin Fc through a reductive alkylation reaction. , but is not limited thereto, and this corresponds to one example.
- the N-terminal amino group of the immunoglobulin Fc region is linked to an oxygen atom located at one end of PEG through a linker functional group having a structure of -CH 2 CH 2 CH 2 -, -PEG-O -CH 2 CH 2 CH 2 NH- It is possible to form a structure such as immunoglobulin Fc, and through a thioether bond, one end of PEG is linked to a sulfur atom located at a cysteine of a peptide to form a structure.
- the above-mentioned thioether bond is may contain the structure of
- the reactive group of the linker may be linked to -NH 2 located at the N-terminus of the immunoglobulin Fc region, but this corresponds to one example.
- the peptide according to the present invention may be linked to a linker having a reactive group through the C-terminus, but this corresponds to one example.
- C-terminus refers to the carboxy terminus of a peptide, and refers to a position capable of binding to a linker for the purpose of the present invention.
- it may include all amino acid residues around the C-terminus as well as the most terminal amino acid residue at the C-terminus, and specifically includes the first to 20th amino acid residues from the most terminal. can, but is not limited thereto.
- conjugate may have increased durability of effect compared to X in which F is not modified, and such a conjugate includes all of the above-described forms as well as forms encapsulated in biodegradable nanoparticles.
- F may be an immunoglobulin Fc region, and more specifically, the immunoglobulin Fc region may be derived from IgG, but is not particularly limited thereto.
- the F immunoglobulin Fc region
- the F is a dimer consisting of two polypeptide chains, and one end of L is linked to only one of the two polypeptide chains.
- it is not limited thereto.
- immunoglobulin Fc region refers to a region including heavy chain constant region 2 (CH2) and/or heavy chain constant region 3 (CH3), excluding the heavy and light chain variable regions of immunoglobulin.
- the immunoglobulin Fc region may be one component constituting a moiety of the conjugate of the present invention.
- the immunoglobulin Fc region may be used interchangeably with “immunoglobulin Fc fragment”.
- Fc region not only the native sequence obtained from papain digestion of immunoglobulin, but also its derivatives, such as one or more amino acid residues in the native sequence, are converted by deletion, insertion, non-conservative or conservative substitution, or a combination thereof, resulting in a native natural sequence. It includes even variants such as sequences that are different from the type. The above derivatives, substituents and variants are premised on retaining the ability to bind FcRn.
- F may be a human immunoglobulin region, but is not limited thereto.
- biocompatible material or “carrier” may refer to the Fc region.
- the F immunoglobulin Fc region
- the F has a structure in which two polypeptide chains are linked by a disulfide bond, and may have a structure in which only one of the two chains is linked through a nitrogen atom, but is not limited thereto.
- the linkage via the nitrogen atom may be linked via reductive amination to the epsilon amino atom or the N-terminal amino group of lysine.
- Reductive amination reaction refers to a reaction in which an amine group or an amino group of a reactant reacts with an aldehyde (that is, a functional group capable of reductive amination) of another reactant to form an amine, and then forms an amine bond by a reduction reaction, It is an organic synthesis reaction well known in the art.
- the F may be connected through the nitrogen atom of the N-terminal proline, but is not limited thereto.
- the immunoglobulin Fc region is one component constituting a moiety of the conjugate of Formula 1 of the present invention, and specifically, may correspond to F in Formula 1 above.
- the immunoglobulin Fc region may include a hinge region in the heavy chain constant region, but is not limited thereto.
- the immunoglobulin Fc region may include a specific hinge sequence at the N-terminus.
- flankinge sequence refers to a region that is located on a heavy chain and forms a dimer of an immunoglobulin Fc region through an inter disulfide bond.
- the hinge sequence may be mutated to have only one cysteine residue by deleting a portion of the hinge sequence having the following amino acid sequence, but is not limited thereto:
- the hinge sequence may include only one cysteine residue by deleting the 8th or 11th cysteine residue in the hinge sequence of SEQ ID NO: 103.
- the hinge sequence of the present invention may be composed of 3 to 12 amino acids, including only one cysteine residue, but is not limited thereto.
- the hinge sequence of the present invention may have the following sequence: Glu-Ser-Lys-Tyr-Gly-Pro-Pro-Pro-Ser-Cys-Pro (SEQ ID NO: 104), Glu-Ser- Lys-Tyr-Gly-Pro-Pro-Cys-Pro-Ser-Pro (SEQ ID NO: 105), Glu-Ser-Lys-Tyr-Gly-Pro-Pro-Cys-Pro-Ser (SEQ ID NO: 106), Glu- Ser-Lys-Tyr-Gly-Pro-Pro-Cys-Pro-Pro (SEQ ID NO: 107), Lys-Tyr-Gly-Pro-Pro-Cys-Pro-Ser (SEQ ID NO: 108), Glu-Ser-Lys- Tyr-Gly-Pro-Pro-Cys (SEQ ID NO: 109), Glu-Lys-Tyr-Gly-Pro-Pro-Cys (SEQ ID NO
- the hinge sequence may include the amino acid sequence of SEQ ID NO: 113 (Pro-Ser-Cys-Pro) or SEQ ID NO: 122 (Ser-Cys-Pro), but is not limited thereto.
- the immunoglobulin Fc region of the present invention may be in a form in which two immunoglobulin Fc chain molecules form a dimer due to the presence of a hinge sequence.
- one end of the linker is a dimer immunoglobulin It may be in a form linked to one chain of the Fc region, but is not limited thereto.
- N-terminus refers to the amino terminus of a protein or polypeptide, and 1, 2, 3, 4, 5, 6, It may include up to 7, 8, 9, or 10 or more amino acids.
- the immunoglobulin Fc region of the present invention may include a hinge sequence at the N-terminus, but is not limited thereto.
- part or all of the heavy chain constant region 1 (CH1) and/or the light chain constant region except for only the heavy and light chain variable regions of immunoglobulin 1 (CL1) may be an extended Fc region. Also, it may be a region in which some fairly long amino acid sequences corresponding to CH2 and/or CH3 have been removed.
- the immunoglobulin Fc region of the present invention comprises 1) a CH1 domain, a CH2 domain, a CH3 domain and a CH4 domain, 2) a CH1 domain and a CH2 domain, 3) a CH1 domain and a CH3 domain, 4) a CH2 domain and a CH3 domain, 5) a combination of one or two or more domains of CH1 domain, CH2 domain, CH3 domain and CH4 domain with an immunoglobulin hinge region (or a part of the hinge region), 6) heavy chain constant region Each domain may be a dimer of a light chain constant region .
- the present invention is not limited thereto.
- the immunoglobulin Fc region may be in the form of a dimer or multimer composed of single-chain immunoglobulins composed of domains of the same origin, but is not limited thereto.
- the immunoglobulin Fc region may be in a dimeric form, and one molecule of X may be covalently linked to one Fc region in a dimeric form (dimeric dimer form), , wherein the immunoglobulin Fc region and X may be linked to each other by a non-peptidyl polymer.
- the immunoglobulin Fc region F is a dimer (dimer) consisting of two polypeptide chains, wherein the Fc region dimers F and X are ethylene glycol They are covalently linked through one and the same linker L containing repeat units.
- X is covalently linked via a linker L to only one of the two polypeptide chains of this Fc region dimer F.
- only one molecule of X is covalently linked via L to one of the two polypeptide chains of the Fc region dimer F to which X is linked.
- F is a homodimer.
- the immunoglobulin Fc region F is a dimer consisting of two polypeptide chains, and one end of L may be connected to only one of the two polypeptide chains, but is not limited thereto.
- the immunoglobulin Fc and X may be linked to each other by a non-peptidyl linker.
- a non-peptidyl linker it is not limited to the examples described above.
- the immunoglobulin Fc region of the present invention includes a native amino acid sequence as well as a sequence derivative thereof.
- An amino acid sequence derivative means that one or more amino acid residues in a natural amino acid sequence have a different sequence by deletion, insertion, non-conservative or conservative substitution, or a combination thereof.
- amino acid residues 214 to 238, 297 to 299, 318 to 322, or 327 to 331 known to be important for binding may be used as suitable sites for modification.
- various types of derivatives are possible, such as a site capable of forming a disulfide bond is removed, some amino acids at the N-terminus of native Fc are removed, or a methionine residue may be added to the N-terminus of native Fc Do.
- the complement binding site eg, the C1q binding site
- the ADCC antibody dependent cell mediated cytotoxicity
- the above-described Fc derivative may exhibit biological activity equivalent to that of the Fc region of the present invention, and may have increased structural stability to heat, pH, etc. of the Fc region.
- the Fc region may be obtained from a native type isolated in vivo from animals such as humans, cows, goats, pigs, mice, rabbits, hamsters, rats or guinea pigs, or obtained from transformed animal cells or microorganisms. It may be recombinant or a derivative thereof.
- the method of obtaining from the native type may be a method of obtaining whole immunoglobulin by isolating it from a living body of a human or animal and then treating it with a proteolytic enzyme. When treated with papain, it is cleaved into Fab and Fc, and when treated with pepsin, it is cleaved into pF'c and F(ab) 2 .
- Fc or pF'c may be separated using size-exclusion chromatography or the like.
- it is a recombinant immunoglobulin Fc region obtained from a human-derived Fc region from a microorganism.
- the immunoglobulin Fc region may have a native sugar chain, an increased sugar chain compared to the native type, a decreased sugar chain compared to the native type, or a form in which the sugar chain is removed.
- Conventional methods such as chemical methods, enzymatic methods, and genetic engineering methods using microorganisms may be used for the increase or decrease or removal of such immunoglobulin Fc sugar chains.
- the immunoglobulin Fc region from which the sugar chains are removed from the Fc has significantly reduced binding to complement (c1q) and reduced or eliminated antibody-dependent cytotoxicity or complement-dependent cytotoxicity, so that unnecessary immune responses in vivo are not induced. does not In this respect, a form more suitable for the original purpose as a drug carrier will be an immunoglobulin Fc region in which sugar chains are removed or non-glycosylated.
- deglycosylation refers to an Fc region from which sugars have been removed with an enzyme
- aglycosylation refers to an Fc region that is not glycosylated by production in prokaryotes, in a more specific embodiment, in E. coli. .
- the immunoglobulin Fc region may be of human or animal origin, such as cattle, goats, pigs, mice, rabbits, hamsters, rats, and guinea pigs, and in a more specific embodiment, it is of human origin.
- the immunoglobulin Fc region may be an Fc region derived from IgG, IgA, IgD, IgE, or IgM, or a combination or hybrid thereof. In a more specific embodiment, it is derived from IgG or IgM, which is most abundant in human blood, and in a more specific embodiment, it is derived from IgG, which is known to enhance the half-life of ligand binding proteins. In an even more specific embodiment, the immunoglobulin Fc region is an IgG4 Fc region, and in the most specific embodiment, the immunoglobulin Fc region is a non-glycosylated Fc region derived from human IgG4, but is not limited thereto.
- the immunoglobulin Fc region is a fragment of human IgG4 Fc, and is a homologous type in which two monomers are linked through a disulfide bond (inter-chain form) between cysteine, amino acid 3 of each monomer. It may be in the form of a dimer, wherein each monomer of the homodimer is independently an internal disulfide bond between cysteines at positions 35 and 95 and an internal disulfide bond between cysteines at positions 141 and 199, that is, two internal It may have/have disulfide bonds (intra-chain form).
- the number of amino acids of each monomer may consist of 221 amino acids, and the amino acids forming the homodimer may consist of a total of 442 amino acids, but is not limited thereto.
- two monomers having the amino acid sequence of SEQ ID NO: 123 (consisting of 221 amino acids) form a homodimer through a disulfide bond between cysteine, the 3rd amino acid of each monomer, and the homodimer
- the monomers of may each independently form an internal disulfide bond between cysteines at positions 35 and 95 and an internal disulfide bond between cysteines at positions 141 and 199, but is not limited thereto.
- F of Formula 1 may include a monomer having an amino acid sequence of SEQ ID NO: 123, and F may be a homodimer of a monomer having an amino acid sequence of SEQ ID NO: 123, but is not limited thereto.
- the immunoglobulin Fc region may be a homodimer comprising the amino acid sequence of SEQ ID NO: 124 (consisting of 442 amino acids), but is not limited thereto.
- the immunoglobulin Fc region and X may not be glycosylated, but is not limited thereto.
- the term "combination" with respect to an immunoglobulin Fc region means that when a dimer or multimer is formed, a polypeptide encoding a single-chain immunoglobulin Fc region of the same origin binds to a single-chain polypeptide of a different origin. means to form That is, it is possible to prepare a dimer or multimer from two or more fragments selected from the group consisting of IgG Fc, IgA Fc, IgM Fc, IgD Fc and IgE Fc fragment.
- hybrid is a term meaning that sequences corresponding to immunoglobulin Fc fragments of two or more different origins exist in a single-chain immunoglobulin constant region.
- various types of hybrids are possible. That is, a hybrid of domains consisting of 1 to 4 domains from the group consisting of CH1, CH2, CH3 and CH4 of IgG Fc, IgM Fc, IgA Fc, IgE Fc and IgD Fc is possible, and may include a hinge.
- IgG can also be divided into subclasses of IgG1, IgG2, IgG3 and IgG4, and in the present invention, a combination thereof or hybridization thereof is also possible. Specifically, they are subclasses of IgG2 and IgG4, and most specifically, an Fc fragment of IgG4 having little effector function such as complement dependent cytotoxicity (CDC).
- CDC complement dependent cytotoxicity
- conjugate may have an increased duration of effect compared to native GLP-1, GIP, or glucagon, or compared to X in which F is not modified. It includes all types of particles and the like, but is not limited thereto.
- conjugate may have an increased duration of effect compared to native GLP-1, GIP, or glucagon, or compared to X in which F is not modified. It includes all types of particles encapsulated.
- the detailed description or claims of the "peptide” or the “conjugate” in which such a peptide is covalently linked to a biocompatible material according to the present invention, as well as the corresponding peptide or conjugate, are It is also applied to the category including the form of a salt of a peptide or a conjugate (eg, a pharmaceutically acceptable salt of the peptide), or a solvate thereof. Therefore, even if only “peptide” or “conjugate” is described in the specification, the description also applies to the specific salt, the specific solvate, and the specific solvate of the specific salt.
- Such salt form may be, for example, a form using any pharmaceutically acceptable salt.
- the type of the salt is not particularly limited. However, it is preferable that the form is safe and effective for an individual, such as a mammal, but is not particularly limited thereto.
- the type of the salt is not particularly limited. However, it is preferable that the form is safe and effective for an individual, such as a mammal, but is not particularly limited thereto.
- pharmaceutically acceptable means a substance that can be effectively used for a desired purpose without causing excessive toxicity, irritation, or allergic reaction within the scope of medical judgment.
- salts derived from pharmaceutically acceptable inorganic acids, organic acids, or bases include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, perchloric acid, fumaric acid, maleic acid, phosphoric acid, glycolic acid, lactic acid, salicylic acid, succinic acid, toluene-p-sulfonic acid, tartaric acid, acetic acid, citric acid, methanesulfonic acid, formic acid , benzoic acid, malonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, and the like.
- Salts derived from suitable bases may include alkali metals such as sodium and potassium, alkaline earth metals such as magnesium, and ammonium.
- solvate refers to a compound in which the peptide or salt thereof according to the present invention forms a complex with a solvent molecule.
- a composition comprising the peptide may be used for preventing or treating a neurodegenerative disease.
- composition according to the present invention may include a peptide (eg, the peptide itself or a long-acting conjugate to which a biocompatible material is bound), specifically, it may include a pharmacologically effective amount of a peptide or a long-acting conjugate thereof. . In addition, it may further include a pharmaceutically acceptable carrier.
- a peptide eg, the peptide itself or a long-acting conjugate to which a biocompatible material is bound
- it may include a pharmacologically effective amount of a peptide or a long-acting conjugate thereof.
- it may further include a pharmaceutically acceptable carrier.
- prevention refers to any action that inhibits or delays the onset of a neurodegenerative disease by administration of the peptide (eg, the peptide itself or a long-acting conjugate to which a biocompatible material is bound) or a composition comprising the same and “treatment” refers to any action in which the symptoms of a neurodegenerative disease are improved or beneficial by administration of the peptide (eg, the peptide itself or a long-acting conjugate to which a biocompatible material is bound) or a composition comprising the same.
- the term "administration” means introducing a predetermined substance to a patient by any suitable method, and the route of administration of the composition is not particularly limited thereto, but any general route through which the composition can reach an in vivo target It can be administered through, for example, intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, topical administration, intranasal administration, intrapulmonary administration, or rectal administration, etc. can be administered through, for example, intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, topical administration, intranasal administration, intrapulmonary administration, or rectal administration, etc. can be administered through, for example, intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, topical administration, intranasal administration, intrapulmonary administration, or rectal administration, etc. can be administered through, for example, intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous
- the triple activator having activity on both long-acting glucagon, GLP-1, and GIP receptors of the present invention or a long-acting conjugate thereof is administered to chronic patients who must be administered daily due to a dramatic increase in the blood half-life and the sustained effect in vivo It has the great advantage of improving the quality of life of patients by reducing the number of times, which is a great help in the treatment of neurodegenerative diseases.
- the triple activator or a long-acting conjugate thereof has an effect of significantly reducing the symptoms of neurodegenerative diseases and/or preventing neurodegenerative diseases such as delaying the recurrence of symptoms of neurodegenerative diseases. It is of great help in the prevention and/or treatment of diseases.
- neurodegenerative disease refers to diseases that cause various symptoms while degenerative changes appear in nerve cells of the central nervous system. , specifically cognitive function, learning or memory, impaired hand/foot sensation, or neuropathy resulting in organ function including the stomach and the like. Specifically, a specific group of brain cells in the brain and spinal cord gradually loses their functions and the most important cranial nerve cells for information transmission in the cranial nervous system are killed, problems with the formation or function of synapses that transmit information between cranial nerve cells and cranial nerve cells, cranial nerves It is known to be caused by an ideal increase or decrease in the electrical activity of
- ALS Amyotrophic lateral sclerosis
- PSP progressive supranuclear palsy
- MSA multiple system atrophy
- Lewy body dementia Parkinson's disease dementia
- epilepsy stroke
- Huntington's chorea brain hypoxia
- peripheral neuropathy memory impairment
- memory loss forgetfulness pick disease
- creutzfeld-kacob disease nerve damage due to side effects of diabetes, etc. not limited
- the neurodegenerative disease may be Parkinson's disease, or stroke.
- the neurodegenerative disease is Parkinson's disease.
- Parkinson's disease can be associated with oxidative stress, an inflammatory response, apoptosis, loss of neurons, in particular loss of dopaminergic neurons, eg, loss of the substantia nigra, resulting in dopamine deficiency.
- the neurodegenerative disease may be Alzheimer's disease.
- Alzheimer's disease is one of the most common degenerative brain diseases that cause dementia, and collectively refers to diseases that cause various symptoms while degenerative changes appear in nerve cells of the central nervous system. Specifically, cognitive function, learning or memory may be impaired, hand/foot sensation may be impaired, or neuropathy causing organ functions including the stomach and the like.
- cognitive function, learning or memory may be impaired, hand/foot sensation may be impaired, or neuropathy causing organ functions including the stomach and the like.
- psycho-behavioral symptoms such as personality changes, agitation, depression, delusions, hallucinations, increased aggression, and sleep disturbance are common. Or even physical complications such as urinary incontinence, infection, and pressure sores may appear.
- brain pathological findings appear limited to the hippocampus and entorhinal cortex, which are the main brain regions responsible for memory, in the early stages of the disease, but gradually spread to the entire brain via the parietal and frontal lobes. According to the progression of these brain pathology invasion sites, memory deterioration appears mainly at the beginning, but as it progresses, the clinical symptoms become diversified and become more severe as it progresses.
- Alzheimer's disease a specific group of brain cells in the brain and spinal cord gradually loses their functions and the most important cranial nerve cells for information transmission in the cranial nervous system are killed, problems with the formation or function of synapses that transmit information between cranial nerve cells and cranial nerve cells, cranial nerves It is known to be caused by an ideal increase or decrease in the electrical activity of Alzheimer's disease may also be referred to as Alzheimer's disease (AD). According to the age of onset, Alzheimer's disease can be classified into early-onset (elderly) Alzheimer's disease when the onset is under the age of 65, and into late-onset (old-age) Alzheimer's disease when it occurs in the age of 65 or older, but is not limited thereto.
- Alzheimer's disease may be associated with oxidative stress and neuronal loss.
- the neurodegenerative disease is progressive supranuclear palsy. Progressive supranuclear palsy may be associated with neuronal loss, particularly loss of dopaminergic neurons.
- the neurodegenerative disease is multiple system atrophy. Multiple system atrophy may be associated with neuronal loss, particularly loss of dopaminergic neurons.
- the neurodegenerative disease is Lewy body dementia.
- Lewy body dementia may be associated with neuronal loss, particularly loss of dopaminergic neurons.
- Lewy body dementia is the second most common cause of dementia after Alzheimer's disease among neurodegenerative diseases observed in the elderly, accounting for about 20%.
- Lewy body dementia may be associated with Parkinson's disease.
- the neurodegenerative disease is epilepsy.
- Epilepsy epilepsy
- epilepsy refers to a brain disease in which temporary paralysis of brain functions, such as loss of consciousness, seizures, and behavioral changes, which occurs due to temporary abnormalities in brain nerve cells to induce an over-excited state, occurs chronically and repeatedly.
- interconnected nerve cells exchange information through microscopic electrical signals. When these normal electrical signals are abnormally and incorrectly released, seizures occur.
- the neurodegenerative disease is Parkinson's disease dementia.
- Parkinson's disease dementia may be associated with neuronal loss, particularly loss of dopaminergic neurons.
- Parkinson's disease dementia is associated with Parkinson's disease.
- Examples include a lack of dopamine due to the loss of dopamine-producing cells, and widespread neurological abnormalities due to denaturation of alpha-synuclein protein.
- Dopamine is an important neurotransmitter that acts on the basal ganglia of the brain so that the body can precisely move as desired. In the substantia nigra of the midbrain, there are cells that produce dopamine, and as these cells are lost for some reason, dopamine becomes insufficient, which causes movement disorders to appear.
- the Lewy body formed by the denaturation of a protein called alpha-synuclein accumulates in the brain cortex, it becomes Lewy body dementia.
- brain cells die due to abnormal protein pair in the brain, which means that the brain function responsible for behavior and body functions is impaired.
- neurological abnormalities such as hallucinations, hallucinations, REM sleep disturbances, and olfactory disturbances appear in patients with Parkinson's disease.
- the neurodegenerative disease is stroke.
- Stroke may be associated with loss of neurons caused by ischemia, where ischemia may be caused by blockage (eg, thrombosis or arterial embolism) or bleeding.
- triple activator peptide having activity on both glucagon, GLP-1 and GIP receptors of the present invention, or a long-acting conjugate of this peptide provides neuroprotective and/or neurogenic effects, and may also provide dopaminergic cytoprotective effects. , but not limited thereto.
- Triple activator peptides having activity on both glucagon, GLP-1 and GIP receptors or long-acting conjugates thereof may provide a disease-modifying effect in neurodegenerative diseases such as Parkinson's disease, and neurodegenerative diseases such as stroke. .
- administration of a triple activator peptide having activity on both glucagon, GLP-1 and GIP receptors, or a long-acting conjugate thereof can improve quality of life by slowing the progression of neuroprotection and neurogenesis, thereby preventing neurodegenerative diseases.
- Suitable for treatment in an early stage of the disease but not limited thereto.
- the triple activator having activity on both glucagon, GLP-1 and GIP receptors of the present invention or a long-acting conjugate of this peptide provides neuroprotective and/or neurogenic effects, specifically, a protective effect against oxidative stress, final It provides an effect of reducing glycation products, an anti-inflammatory effect, and a reducing effect of a substance causing Alzheimer's disease, but is not limited thereto.
- Triple activator peptides having activity on both glucagon, GLP-1 and GIP receptors or long-acting conjugates thereof may provide a disease-modifying effect in neurodegenerative diseases, specifically Alzheimer's disease.
- administering can slow the progression of the disease and improve quality of life, so Alzheimer's disease Suitable for treatment in the initial stage of, but not limited to.
- composition of the present invention may prevent or treat neurodegenerative diseases by performing one or more of the following characteristics, but is not limited thereto:
- Dopaminergic cells are cells that are reduced/destroyed as neurodegenerative diseases progress, and their protective effect means that various neurodegenerative diseases can be treated. It is an increasing cell, and its decrease means that the neurodegenerative disease is treated / alleviated and excessive immune action is suppressed. This means that it has been cured/relieved.
- the motor ability is reduced, and the properties of the composition of the present invention for alleviating the ataxia symptoms in which the motor ability is reduced as such are the treatment / alleviation of the neurodegenerative disease, thereby showing the prevention or therapeutic effect of the neurodegenerative disease. can, but is not limited thereto.
- composition of the present invention may prevent or treat neurodegenerative diseases by performing one or more of the following characteristics, but is not limited thereto:
- Amyloid beta protein is a protein known as one of the causative substances of neurodegenerative diseases, and its decrease means that neurodegenerative diseases are treated/alleviated by inhibiting hyperphosphorylation of tau protein, and AGE (advanced glycation end products) is This bound protein or lipid is known to be a substance that aggravates the symptoms of neurodegenerative diseases associated with aging, and its reduction means that the neurodegenerative diseases are treated / alleviated. In the case of the onset of a neurodegenerative disease, inflammation and / or oxidative stress increases in an individual, and its reduction is the treatment / alleviation of the neurodegenerative disease, and may indicate the prevention or therapeutic effect of the neurodegenerative disease, but is not limited thereto.
- the pharmaceutical composition of the present invention may further include a pharmaceutically acceptable carrier, excipient or diluent.
- a pharmaceutically acceptable carrier excipient or diluent.
- Such pharmaceutically acceptable carriers, excipients, or diluents may be non-naturally occurring.
- the term "pharmaceutically acceptable” means a sufficient amount to exhibit a therapeutic effect and does not cause side effects, and the type of disease, the patient's age, weight, health, sex, and the patient's sensitivity to the drug , administration route, administration method, frequency of administration, treatment period, combination or drugs used at the same time can be easily determined by those skilled in the art according to factors well known in the medical field.
- the pharmaceutical composition including the peptide of the present invention may further include a pharmaceutically acceptable excipient.
- the excipient is not particularly limited thereto, but in the case of oral administration, a binder, a lubricant, a disintegrant, a solubilizer, a dispersant, a stabilizer, a suspending agent, a color, a fragrance, etc. may be used, and in the case of an injection, a buffer, a preservative, An analgesic agent, a solubilizer, an isotonic agent, a stabilizer, etc. can be mixed and used, and in the case of topical administration, a base, excipient, lubricant, preservative, etc. can be used.
- the formulation of the composition of the present invention can be prepared in various ways by mixing with the pharmaceutically acceptable excipients as described above.
- it may be prepared in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like, and in the case of injections, it may be prepared in the form of unit dose ampoules or multiple doses.
- it can be formulated as a solution, suspension, tablet, pill, capsule, sustained release formulation, and the like.
- suitable carriers, excipients and diluents for formulation include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, Microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate or mineral oil may be used.
- it may further include a filler, an anti-aggregating agent, a lubricant, a wetting agent, a flavoring agent, a preservative, and the like.
- the pharmaceutical composition of the present invention is any one selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, internal solutions, emulsions, syrups, sterile aqueous solutions, non-aqueous solvents, freeze-dried preparations and suppositories may have the form of
- composition is formulated in a dosage form suitable for administration in a patient's body according to a conventional method in the pharmaceutical field, specifically, a formulation useful for administration of a protein drug, and administration commonly used in the art.
- the conjugate can be used by mixing with various pharmaceutically acceptable carriers, such as physiological saline or organic solvents, and carbohydrates such as glucose, sucrose or dextran, ascorbic acid (ascorbic acid) to increase stability or absorption. acid) or antioxidants such as glutathione, chelating agents, low molecular weight proteins or other stabilizers, etc. may be used as agents.
- pharmaceutically acceptable carriers such as physiological saline or organic solvents
- carbohydrates such as glucose, sucrose or dextran, ascorbic acid (ascorbic acid) to increase stability or absorption. acid) or antioxidants such as glutathione, chelating agents, low molecular weight proteins or other stabilizers, etc.
- the dosage and frequency of administration of the pharmaceutical composition of the present invention is determined according to the type of drug as the active ingredient, along with several related factors such as the disease to be treated, the route of administration, the age, sex and weight of the patient, and the severity of the disease.
- the composition of the present invention may include the peptide or a long-acting conjugate comprising the same in a pharmaceutically effective amount, but is not limited thereto.
- the inclusion of the peptide or the long-acting conjugate in a pharmaceutically effective amount means the degree to which the desired pharmacological activity (e.g., prevention, improvement or treatment of neurodegenerative diseases) can be obtained due to the peptide or the long-acting conjugate,
- toxicity or side effects do not occur in the administered subject or may mean a pharmaceutically acceptable level as a minor level, but is not limited thereto.
- Such a pharmaceutically effective amount may be determined by comprehensively considering the number of administration, patient, formulation, and the like.
- the pharmaceutical composition of the present invention may contain the component (active ingredient) in an amount of 0.01 to 99% by weight to volume.
- the total effective amount of the composition of the present invention may be administered to a patient as a single dose, or may be administered by a fractionated treatment protocol in which multiple doses are administered for a long period of time.
- the pharmaceutical composition of the present invention may vary the content of the active ingredient depending on the severity of the disease.
- the preferred total dose of the triple active agent or long-acting conjugate thereof of the present invention may be about 0.0001 mg to 500 mg per kg of body weight of the patient per day.
- the dose of the triple active agent or its conjugate is determined by considering various factors such as the age, weight, health status, sex, severity of disease, diet and excretion rate of the patient, as well as the administration route and number of treatments of the pharmaceutical composition.
- the pharmaceutical composition according to the present invention is not particularly limited in its formulation, administration route and administration method as long as the effect of the present invention is exhibited.
- the pharmaceutical composition of the present invention has excellent in vivo persistence and potency, and can significantly reduce the number and frequency of administration of the pharmaceutical preparation of the present invention.
- Another aspect embodying the present invention provides a food composition for the prevention or improvement of neurodegenerative diseases, comprising the triple activator (peptide) and/or a long-acting conjugate of the triple activator.
- the peptides, long-acting conjugates, neurodegenerative diseases, etc. are as described above.
- the food composition may be used as a health functional food.
- the peptide peptide itself or its long-acting conjugate
- the mixing amount of the active ingredient may be appropriately determined according to the purpose of use (prevention, health or therapeutic treatment).
- health functional food in the present invention refers to a food manufactured and processed by extracting, concentrating, refining, mixing, etc., a specific ingredient as a raw material or a specific ingredient contained in a food raw material for the purpose of health supplementation, It refers to a food designed and processed to sufficiently exert biological control functions such as biological defense, regulation of biological rhythm, prevention and recovery of disease, etc., by the above ingredients, and the composition for health food is used for prevention of diseases and prevention of diseases. It can perform functions related to recovery, etc.
- Another embodiment embodying the present invention is a neurodegenerative disease comprising administering to an individual in need thereof, a long-acting conjugate of the triple activator (peptide) and/or the triple activator, or a composition comprising the same. It provides a method for preventing or treating
- triple activator and/or a long-acting conjugate of the triple activator, or a composition comprising the same, a neurodegenerative disease, prevention and treatment are the same as described above.
- the subject is a subject suspected of a neurodegenerative disease
- the subject suspected of a neurodegenerative disease refers to mammals including rats, livestock, etc. including humans that have or may develop the disease, but of the present invention
- Subjects that can be treated with the peptide and/or conjugate, or the composition comprising the same, are included without limitation.
- the term "administration” means introducing a predetermined substance to a patient by any suitable method, and the route of administration of the composition is not particularly limited thereto, but any general route through which the composition can reach an in vivo target It may be administered through, for example, intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, topical administration, intranasal administration, intrapulmonary administration, or rectal administration.
- routes of administration of the composition is not particularly limited thereto, but any general route through which the composition can reach an in vivo target It may be administered through, for example, intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, topical administration, intranasal administration, intrapulmonary administration, or rectal administration.
- the method of the present invention may include administering a pharmaceutical composition comprising the triple active agent or a long-acting conjugate thereof in a pharmaceutically effective amount.
- a suitable total daily amount may be determined by a treating physician within the scope of sound medical judgment, and may be administered once or divided into several doses.
- a specific therapeutically effective amount for a particular patient depends on the type and extent of the response to be achieved, the specific composition, including whether other agents are used, if necessary, the specific composition, the patient's age, weight, general health, It is preferable to apply differently depending on various factors including sex and diet, administration time, administration route and secretion rate of the composition, treatment period, drugs used together or concurrently with a specific composition, and similar factors well known in the pharmaceutical field.
- Another aspect embodying the present invention is the use of a composition comprising the triple active peptide or a long-acting conjugate of the peptide in the manufacture of a medicament for the prevention or treatment of a neurodegenerative disease.
- the peptide and/or conjugate, or a composition comprising the same, neurodegenerative disease, prevention and treatment are as described above.
- Another aspect embodying the present invention is to provide the use of a peptide and/or conjugate, or a composition comprising the same for the prevention or treatment of neurodegenerative diseases.
- the peptide and/or conjugate, or a composition comprising the same, a neurodegenerative disease, prevention and treatment are as described above.
- Another aspect embodying the present invention is dopaminergic cell protection use of the peptide or a composition comprising a long-acting conjugate of the peptide.
- Another embodiment embodying the present invention is a dopamine cell protection composition comprising the peptide or a long-acting conjugate of the peptide.
- Another aspect of the present invention provides a method for protecting dopaminergic cells, comprising administering the above-described peptide of the present invention or a long-acting conjugate of the peptide to an individual in need of dopaminergic cell protection in an effective amount.
- an amino acid denoted by X is a non-natural amino acid Aib (2-aminoisobutyric acid), and an underlined amino acid means that the underlined amino acids form a ring with each other.
- CA means 4-imidazoacetyl (4-imidazoacetyl).
- the triple activator peptide is used as a triple activator obtained by amidation of the C-terminus, if necessary.
- the triple activator of Example 1 (SEQ ID NOs: 21, 22, 42, 43, 50, 77, and 96) for pegylation to the cysteine residues, the molar ratio of the triple activator to maleimide-PEG-aldehyde is 1:1 to 3, and the protein concentration is 1 to 5 mg/ml, and 0.5 to 3 at low temperature. reacted for an hour. At this time, the reaction was carried out in an environment in which 20 to 60% isopropanol was added to 50 mM Tris buffer (pH 7.5). After the reaction was completed, the reaction solution was applied to SP Sepharose HP (GE healthcare, USA) to purify the tri-activator mono-pegylated to cysteine.
- SP Sepharose HP GE healthcare, USA
- the purified mono-pegylated triple activator and immunoglobulin Fc are reacted at a molar ratio of 1:1 to 5 and a protein concentration of 10 to 50 mg/ml at 4 to 8° C. for 12 to 18 hours. made it
- the reaction was carried out in an environment in which 10 to 50 mM sodium cyanoborohydride and 10 to 30% isopropanol as reducing agents were added to 100 mM potassium phosphate buffer (pH 6.0). After completion of the reaction, the reaction solution was applied to the butyl sepharose FF purification column (GE healthcare, USA) and the Source ISO purification column (GE healthcare, USA) to purify the complex containing the triple activator and immunoglobulin Fc.
- This purified long-acting conjugate has a structure in which a triple active peptide, a polyethylene glycol (PEG) linker and an Fc dimer are covalently linked in a molar ratio of 1:1:1, and the PEG linker is one of the two polypeptide chains of the Fc dimer. connected to only one chain.
- PEG polyethylene glycol
- two monomers having the amino acid sequence of SEQ ID NO: 123 form a homodimer through a disulfide bond between cysteine, the 3rd amino acid of each monomer, and the monomer of the homodimer Each independently formed an internal disulfide bond between cysteines at positions 35 and 95 and an internal disulfide bond between cysteines at positions 141 and 199.
- the triple activator obtained by amidation of the C-terminus of the triple activator of SEQ ID NO: 21 and the conjugate in which immunoglobulin Fc is linked through PEG are referred to as 'conjugate comprising SEQ ID NO: 21 and immunoglobulin Fc' or 'SEQ ID NO: 21 ', and these may be used interchangeably herein.
- the triple activator obtained by amidation of the C-terminus of the triple activator of SEQ ID NO: 22 and the conjugate in which immunoglobulin Fc is linked through PEG are referred to as 'conjugate comprising SEQ ID NO: 22 and immunoglobulin Fc' or 'SEQ ID NO: 22 ', and these may be used interchangeably herein.
- the triple activator obtained by amidation of the C-terminus of the triple activator of SEQ ID NO: 42 and the conjugate in which immunoglobulin Fc is linked through PEG are referred to as 'conjugate comprising SEQ ID NO: 42 and immunoglobulin Fc' or 'SEQ ID NO: 42 ', and these may be used interchangeably herein.
- the triple activator obtained by amidation of the C-terminus of the triple activator of SEQ ID NO: 43 and the conjugate in which immunoglobulin Fc is linked through PEG are referred to as 'conjugate comprising SEQ ID NO: 43 and immunoglobulin Fc' or 'SEQ ID NO: 43 It was named as a 'long-acting conjugate of
- the triple activator obtained by amidation of the C-terminus of the triple activator of SEQ ID NO: 50 and the conjugate in which immunoglobulin Fc is linked through PEG are referred to as 'conjugate comprising SEQ ID NO: 50 and immunoglobulin Fc' or 'SEQ ID NO: 50 ', and these may be used interchangeably herein.
- the triple activator obtained by amidation of the C-terminus of the triple activator of SEQ ID NO: 77 and the conjugate in which immunoglobulin Fc is linked through PEG are referred to as 'conjugate comprising SEQ ID NO: 77 and immunoglobulin Fc' or 'SEQ ID NO: 77 It was named as a 'long-acting conjugate of
- the triple activator obtained by amidation of the C-terminus of the triple activator of SEQ ID NO: 96 and the conjugate in which immunoglobulin Fc is linked through PEG are referred to as 'conjugate comprising SEQ ID NO: 96 and immunoglobulin Fc' or 'SEQ ID NO: 96 ', and these may be used interchangeably herein.
- Each of the above cell lines was transformed to express human GLP-1 receptor, human GCG receptor and human GIP receptor genes in Chinese hamster ovary (CHO), respectively, and is suitable for measuring the activities of GLP-1, GCG and GIP. Therefore, the activity for each part was measured using each transformed cell line.
- Human GLP-1 was serially diluted from 50 nM to 0.000048 nM by 4 times to measure the GLP-1 activity of the triple activator and its long-acting conjugate prepared in Examples 1 and 2, and prepared in Examples 1 and 2
- the triple activator and its long-acting conjugate were serially diluted from 400 nM to 0.00038 nM by 4 times.
- the culture medium was removed from the cultured CHO cells expressing the human GLP-1 receptor, 5 ⁇ l of each serially diluted substance was added to the cells, and then 5 ⁇ l of a buffer containing cAMP antibody was added for 15 minutes. during incubation at room temperature.
- human GCG was serially diluted from 50 nM to 0.000048 nM by 4 times, and the triple activator prepared in Examples 1 and 2 was serially diluted. and its long-acting conjugate were serially diluted from 400 nM to 0.00038 nM in 4-fold increments.
- the culture medium was removed from the cultured CHO cells expressing human GCG receptor, 5 ⁇ l of each serially diluted substance was added to the cells, and 5 ⁇ l of a buffer containing cAMP antibody was added thereto, followed by room temperature for 15 minutes.
- human GIP was serially diluted from 50 nM to 0.000048 nM by 4 times, and the triple activity prepared in Examples 1 and 2 above.
- the sieve and its long-acting conjugate were serially diluted from 400 nM to 0.00038 nM in 4-fold increments.
- the culture medium was removed from the cultured CHO cells expressing the human GIP receptor, 5 ⁇ l of each serially diluted substance was added to the cells, and 5 ⁇ l of a buffer containing cAMP antibody was added thereto, followed by room temperature for 15 minutes.
- the novel triple activator long-acting conjugate prepared above has a function as a triple activator capable of activating all of the GLP-1 receptor, GIP receptor and glucagon receptor. It can be used as a therapeutic agent for patients with neurodegenerative diseases including nerve damage.
- Acute Parkinson's disease animal model was administered by intraperitoneal administration of 30 mg/kg of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) once a day for 7 days to C57BL/6 mice to induce dopaminergic neurons. It was produced by inducing cell loss. During the study period, mice were housed in groups and had free access to water. The test group was divided into group 1 (excipient control), group 2 (MPTP-excipient control), and group 3 (MPTP-SEQ ID NO: 42 long-acting conjugate 5.03 nmol/kg), and 10 mice per group were tested. The excipient and the long-acting conjugate of SEQ ID NO: 42 were administered subcutaneously once 30 minutes after administration of MPTP on the first day. The experiment was terminated on the 7th day. One-way ANOVA was used for statistical treatment.
- the symptoms of ataxia were measured through the Rotarod test.
- the mouse is allowed to move on the rotating cylinder for up to 180 seconds.
- the rotational speed of the cylinder started at 10 rpm and gradually increased, and was set to 25 rpm after 100 seconds. After 100 seconds, the rotation speed of the cylinder was fixed at 25 rpm. In this way, the time until it falls off the rotating cylinder was measured, and the average value of the fall latency was calculated by performing a total of three times.
- the third group administered with SEQ ID NO: 42 long-acting conjugate significantly improved the fall potential time.
- mice After killing the mice in each group after the behavioral test (Rotarod test) was completed, brain tissue was extracted. The extracted brain tissue was immersed and fixed in freshly prepared 4% paraformaldehyde for 24 hours, and after dehydration, a frozen section slide was prepared for tissue immunostaining test. Thereafter, immunostaining was performed using an antibody against TH (Tyrosine hydroxylase), which is involved in dopamine synthesis. Dopamine cytoprotective activity was measured by measuring optical density and cell number for TH stained in the striatum and substantia nigra, and quantified using Image J program.
- TH Teyrosine hydroxylase
- the number of TH-stained cells in the third group administered with SEQ ID NO: 42 long-acting conjugate was decreased compared to the decrease in the second group in the number of TH-stained cells in the substantia nigra due to MPTP toxicity. was significantly suppressed.
- mice were administered subcutaneously and intraperitoneally with MPTP 25 mg/kg and probenecid 250 mg/kg twice a week (3.5-day interval) for a total of 5 weeks to prevent long-term dopaminergic neuronal death. produced by induction.
- the test group was divided into group 1 (excipient control), group 2 (MPTP/Probenecid-excipient control), and group 3 (MPTP/Probenecid- SEQ ID NO: 42 long-acting conjugate 5.03 nmol/kg), and 10 mice per group were tested. .
- the excipient and the long-acting conjugate of SEQ ID NO: 42 were administered subcutaneously after administration of MPTP/Probenecid once a week for a total of 6 weeks.
- Microglia are cells responsible for immunity in the brain, and they regulate immunity in the brain through phagocytosis or cytokine secretion in situations such as infection. Microglia were stained from sections of the brain striatum using an antibody against Iba1 protein present in microglia. The stained area was quantified using the image J program.
- the microglia of the second group increased due to the toxicity caused by the MPTP/Probenecid administration, and the microglia were significantly decreased in the third group administered with the SEQ ID NO: 42 long-acting conjugate. became
- Alpha-synuclein is a representative protein that causes Parkinson's disease. When alpha-synuclein in the brain increases and gets tangled with each other, neuronal cell death is induced. Among the proteins in the brain, alpha-synuclein was identified through an enzyme immunoassay (ELISA) method.
- ELISA enzyme immunoassay
- the Db/db mouse is a representative animal model of diabetes, and it is known that the representative characteristics of Alzheimer's disease are well represented through many studies.
- Amyloid beta protein along with excessive phosphorylation of tau protein, is known to be the biggest cause of Alzheimer's disease. After 12 weeks of drug administration, the amount of amyloid beta 1-42 protein in the cerebral cortex of db/db mice was measured by ELISA.
- amyloid beta 1-42 protein was significantly reduced in the group administered with SEQ ID NO: 42 long-acting conjugate compared to the control group administered with the excipient.
- AGEs Advanced glycation end products
- AGEs are sugar-bound proteins or lipids, which aggravate degenerative diseases such as diabetes, arteriosclerosis, and Alzheimer's disease associated with aging.
- the final glycosylation product in the cerebral cortex was quantified through the ELISA method.
- the final glycation product was significantly reduced in the group administered with the SEQ ID NO: 42 long-acting conjugate compared to the control group administered with the excipient.
- the anti-inflammatory effect was evaluated by measuring inflammatory cytokines in the extracted cortical tissue.
- Interleukin-1 beta among inflammatory cytokines was measured using ELISA method.
- interleukin-1 beta was significantly reduced in the group administered with SEQ ID NO: 42 long-acting conjugate compared to the control group administered with the excipient.
- HNE (4-hydroxynonenal) is a by-product of lipid peroxidation under oxidative stress, and forms an HNE-protein complex by combining with proteins in the body.
- the amount of HNE-protein conjugate in the cerebral cortex was measured by ELISA method.
- the HNE-protein conjugate was significantly reduced in the group administered with SEQ ID NO: 42 long-acting conjugate compared to the control group administered with the excipient.
- triple activator peptide or long-acting conjugates thereof of the present invention can effectively treat neurodegenerative diseases, and support that they can be provided as new therapeutic agents for neurodegenerative diseases.
Abstract
Description
서열번호 | 서열 | 정보 |
1 | H X Q G T F T S D V S S Y L D G Q A A K E F I A W L V K G C | |
2 | H X Q G T F T S D V S S Y L D G Q A Q K E F I A W L V K G C | |
3 | H X Q G T F T S D V S S Y L L G Q A A K Q F I A W L V K G G G P S S G A P P P S C | |
4 | H X Q G T F T S D V S S Y L L G Q Q Q K E F I A W L V K G C | |
5 | H X Q G T F T S D V S S Y L L G Q Q Q K E F I A W L V K G G G P S S G A P P P S C | |
6 | H X Q G T F T S D V S S Y L D G Q A A K E F V A W L L K G C | |
7 | H X Q G T F T S D V S K Y L D G Q A A K E F V A W L L K G C | |
8 | H X Q G T F T S D V S K Y L D G Q A A Q E F V A W L L K G C | |
9 | H X Q G T F T S D V S K Y L D G Q A A Q E F V A W L L A G C | |
10 | H X Q G T F T S D V S K Y L D G Q A A Q E F V A W L L A G G G P S S G A P P P S C | |
11 | CA G E G T F T S D L S K Y L D S R R Q Q L F V Q W L K A G G P S S G A P P P S H G | |
12 | CA G E G T F I S D L S K Y M D E Q A V Q L F V E W L M A G G P S S G A P P P S H G | |
13 | CA G E G T F I S D Y S I Q L D E I A V Q D F V E W L L A Q K P S S G A P P P S H G | |
14 | CA G Q G T F T S D Y S I Q L D E I A V R D F V E W L K N G G P S S G A P P P S H G | |
15 | CA G Q G T F T S D L S K Q M D E E A V R L F I E W L K N G G P S S G A P P P S H G | |
16 | CA G Q G T F T S D L S K Q M D S E A Q Q L F I E W L K N G G P S S G A P P P S H G | |
17 | CA G Q G T F T S D L S K Q M D E E R A R E F I E W L L A Q K P S S G A P P P S H G | |
18 | CA G Q G T F T S D L S K Q M D S E R A R E F I E W L K N T G P S S G A P P P S H G | |
19 | CA G Q G T F T S D L S I Q Y D S E H Q R D F I E W L K D T G P S S G A P P P S H G | |
20 | CA G Q G T F T S D L S I Q Y E E E A Q Q D F V E W L K D T G P S S G A P P P S H G | |
21 | Y X Q G T F T S D Y S K Y L D E C R A K E F V Q W L L D H H P S S G Q P P P S | 고리 형성 |
22 | Y X Q G T F T S D Y S K C L D E K R A K E F V Q W L L D H H P S S G Q P P P S | 고리 형성 |
23 | Y X Q G T F T S D Y S K Y L D E C R A K E F V Q W L L A Q K G K K N D W K H N I T | 고리 형성 |
24 | Y X Q G T F T S D Y S K Y L D E C R A K E F V Q W L K N G G P S S G A P P P S | 고리 형성 |
25 | H X Q G T F T S D C S K Y L D E R A A Q D F V Q W L L D G G P S S G A P P P S | |
26 | H X Q G T F T S D C S K Y L D S R A A Q D F V Q W L L D G G P S S G A P P P S | |
27 | H X Q G T F T S D Y S K Y L D E R A C Q D F V Q W L L D Q G G P S S G A P P P S | |
28 | H X Q G T F T S D Y S K Y L D E K R A Q E F V C W L L A Q K G K K N D W K H N I T | |
29 | H X Q G T F T S D Y S K Y L D E K A A K E F V Q W L L N T C | 고리 형성 |
30 | H X Q G T F T S D Y S K Y L D E K A Q K E F V Q W L L D T C | 고리 형성 |
31 | H X Q G T F T S D Y S K Y L D E K A C K E F V Q W L L A Q | 고리 형성 |
32 | H X Q G T F T S D Y S K Y L D E K A C K D F V Q W L L D G G P S S G A P P P S | 고리 형성 |
33 | H X Q G T F T S D Y S I A M D E I H Q K D F V N W L L A Q K C | 고리 형성 |
34 | H X Q G T F T S D Y S K Y L D E K R Q K E F V N W L L A Q K C | 고리 형성 |
35 | H X Q G T F T S D Y S I A M D E I H Q K D F V N W L L N T K C | 고리 형성 |
36 | H X Q G T F T S D Y S K Y L C E K R Q K E F V Q W L L N G G P S S G A P P P S G | 고리 형성 |
37 | H X Q G T F T S D Y S K Y L D E C R Q K E F V Q W L L N G G P S S G A P P P S G | 고리 형성 |
38 | CA X Q G T F T S D K S S Y L D E R A A Q D F V Q W L L D G G P S S G A P P P S S | |
39 | H X Q G T F T S D Y S K Y L D G Q H A Q C F V A W L L A G G G P S S G A P P P S | |
40 | H X Q G T F T S D K S K Y L D E R A C Q D F V Q W L L D G G P S S G A P P P S | |
41 | H X Q G T F T S D K S K Y L D E C A A Q D F V Q W L L D G G P S S G A P P P S | |
42 | Y X Q G T F T S D Y S K Y L D E K R A K E F V Q W L L D H H P S S G Q P P P S C | 고리 형성 |
43 | Y X Q G T F T S D Y S K Y L D E K R A K E F V Q W L L D H H C S S G Q P P P S | 고리 형성 |
44 | H G Q G T F T S D C S K Q L D G Q A A Q E F V A W L L A G G P S S G A P P P S | |
45 | H G Q G T F T S D C S K Y M D G Q A A Q D F V A W L L A G G P S S G A P P P S | |
46 | H G Q G T F T S D C S K Y L D E Q H A Q E F V A W L L A G G P S S G A P P P S | |
47 | H G Q G T F T S D C S K Y L D G Q R A Q E F V A W L L A G G P S S G A P P P S | |
48 | H G Q G T F T S D C S K Y L D G Q R A Q D F V N W L L A G G P S S G A P P P S | |
49 | CA X Q G T F T S D Y S I C M D E I H Q K D F V N W L L N T K | 고리 형성 |
50 | H X Q G T F T S D Y S K Y L D E K R A K E F V Q W L L D H H P S S G Q P P P S C | 고리 형성 |
51 | H X Q G T F T S D Y S K Y L D E K R Q K E F V Q W L L N T C | 고리 형성 |
52 | H X Q G T F T S D Y S K Y L D E K R Q K E F V Q W L L D T C | 고리 형성 |
53 | H X E G T F T S D Y S I A M D E I H Q K D F V N W L L A Q C | 고리 형성 |
54 | H X E G T F T S D Y S I A M D E I H Q K D F V D W L L A E C | 고리 형성 |
55 | H X Q G T F T S D Y S I A M D E I H Q K D F V N W L L A Q C | 고리 형성 |
56 | H X Q G T F T S D Y S K Y L D E K R Q K E F V N W L L A Q C | 고리 형성 |
57 | H X Q G T F T S D Y S I A M D E I H Q K D F V N W L L N T C | 고리 형성 |
58 | H X Q G T F T S D Y S K Y L D E K R Q K E F V Q W L L N T K C | 고리 형성 |
59 | CA X Q G T F T S D Y S I C M D E K H Q K D F V N W L L N T K | 고리 형성 |
60 | CA X Q G T F T S D Y S I A M D E K H C K D F V N W L L N T K | 고리 형성 |
61 | CA X Q G T F T S D Y S I A M D E I A C K D F V N W L L N T K | 고리 형성 |
62 | CA X Q G T F T S D K S K Y L D E R A A Q D F V Q W L L D G G P S S G A P P P S | |
63 | CA X Q G T F T S D C S K Y L D E R A A Q D F V Q W L L D G G P S S G A P P P S | |
64 | Y X Q G T F T S D Y S K Y L D E C A A K E F V Q W L L D H H P S S G Q P P P S | 고리 형성 |
65 | H X Q G T F T S D Y S K C L D E K R A K E F V Q W L L D H H P S S G Q P P P S | 고리 형성 |
66 | Y X Q G T F T S D Y S K Y L D E C R A K D F V Q W L L D H H P S S G Q P P P S | 고리 형성 |
67 | Y X Q G T F T S D Y S K Y L D E C A A K D F V Q W L L D H H P S S G Q P P P S | 고리 형성 |
68 | Y X Q G T F T S D Y S K C L D E K A A K E F V Q W L L D H H P S S G Q P P P S | 고리 형성 |
69 | Y X Q G T F T S D Y S K C L D E R A A K E F V Q W L L D H H P S S G Q P P P S | 고리 형성 |
70 | Y X Q G T F T S D Y S K C L D E K R A K D F V Q W L L D H H P S S G Q P P P S | 고리 형성 |
71 | Y X Q G T F T S D Y S K Y L D E R A C K D F V Q W L L D H H P S S G Q P P P S | 고리 형성 |
72 | Y X Q G T F T S D C S K Y L D E R A A K D F V Q W L L D H H P S S G Q P P P S | 고리 형성 |
73 | CA X Q G T F T S D Y S K Y L D E C R A K E F V Q W L L D H H P S S G Q P P P S | 고리 형성 |
74 | CA X Q G T F T S D Y S K C L D E K R A K E F V Q W L L D H H P S S G Q P P P S | 고리 형성 |
75 | Y X Q G T F T S D Y S K Y L D E K A A K E F V Q W L L D H H P S S G Q P P P S C | 고리 형성 |
76 | Y X Q G T F T S D Y S K Y L D E K R A K D F V Q W L L D H H P S S G Q P P P S C | 고리 형성 |
77 | Y X Q G T F T S D Y S K Y L D E K A A K D F V Q W L L D H H P S S G Q P P P S C | 고리 형성 |
78 | H X Q G T F T S D Y S K Y L D E K R Q K E F V Q W L L D T K C | 고리 형성 |
79 | H X E G T F T S D Y S I A M D E I H Q K D F V N W L L A Q K C | 고리 형성 |
80 | H X E G T F T S D Y S I A M D E I H Q K D F V D W L L A E K C | 고리 형성 |
81 | CA X Q G T F T S D Y S K Y L D E K R Q K E F V Q W L L N T C | 고리 형성 |
82 | CA X Q G T F T S D Y S K Y L D E K R Q K E F V Q W L L D T C | 고리 형성 |
83 | CA X E G T F T S D Y S I A M D E I H Q K D F V N W L L A Q C | 고리 형성 |
84 | CA X E G T F T S D Y S I A M D E I H Q K D F V D W L L A E C | 고리 형성 |
85 | CA X Q G T F T S D Y S I A M D E I H Q K D F V N W L L A Q C | 고리 형성 |
86 | CA X Q G T F T S D Y S K Y L D E K R Q K E F V N W L L A Q C | 고리 형성 |
87 | CA X Q G T F T S D Y S I A M D E I H Q K D F V N W L L N T C | 고리 형성 |
88 | CA X Q G T F T S D Y S K Y L D E K R Q K E F V Q W L L N T K C | 고리 형성 |
89 | CA X Q G T F T S D Y S K Y L D E K R Q K E F V Q W L L D T K C | 고리 형성 |
90 | CA X E G T F T S D Y S I A M D E I H Q K D F V N W L L A Q K C | 고리 형성 |
91 | CA X E G T F T S D Y S I A M D E I H Q K D F V D W L L A E K C | 고리 형성 |
92 | CA X Q G T F T S D Y S I A M D E I H Q K D F V N W L L A Q K C | 고리 형성 |
93 | CA X Q G T F T S D Y S K Y L D E K R Q K E F V N W L L A Q K C | 고리 형성 |
94 | CA X Q G T F T S D Y S I A M D E I H Q K D F V N W L L N T K C | 고리 형성 |
95 | Y X Q G T F T S D Y S K Y L D E K R A K E F V Q W L L C H H P S S G Q P P P S | 고리 형성 |
96 | Y X Q G T F T S D Y S K Y L D E K R A K E F V Q W L L D H C P S S G Q P P P S | 고리 형성 |
97 | Y X Q G T F T S D Y S K Y L D E K R A K E F V Q W L L D C H P S S G Q P P P S | 고리 형성 |
98 | Y X Q G T F T S D Y S K A L D E K A A K E F V N W L L D H H P S S G Q P P P S C | 고리 형성 |
99 | Y X Q G T F T S D Y S K A L D E K A A K D F V N W L L D H H P S S G Q P P P S C | 고리 형성 |
100 | Y X Q G T F T S D Y S K A L D E K A A K E F V Q W L L D Q H P S S G Q P P P S C | 고리 형성 |
101 | Y X Q G T F T S D Y S K A L D E K A A K E F V N W L L D Q H P S S G Q P P P S C | 고리 형성 |
102 | Y X Q G T F T S D Y S K A L D E K A A K D F V N W L L D Q H P S S G Q P P P S C | 고리 형성 |
천연형 펩타이드 대비in vitro 활성 (%) | |||
서열번호 | vs GLP-1 | vs Glucagon | vs GIP |
1 | 3.2 | <0.1 | <0.1 |
2 | 5.9 | <0.1 | <0.1 |
3 | 1.8 | <0.1 | <0.1 |
4 | 8.5 | <0.1 | <0.1 |
5 | 42.1 | <0.1 | <0.1 |
6 | 17.0 | <0.1 | <0.1 |
7 | 13.7 | <0.1 | <0.1 |
8 | 14.2 | 0.10 | <0.1 |
9 | 32.1 | 0.13 | <0.1 |
10 | 46.0 | <0.1 | <0.1 |
11 | 1.4 | <0.1 | <0.1 |
12 | 0.4 | <0.1 | <0.1 |
13 | < 0.1 | < 0.1 | < 0.1 |
14 | 28.0 | < 0.1 | < 0.1 |
15 | 79.2 | <0.1 | <0.1 |
16 | 2.1 | < 0.1 | < 0.1 |
17 | 0.2 | < 0.1 | < 0.1 |
18 | <0.1 | <0.1 | <0.1 |
19 | <0.1 | <0.1 | <0.1 |
20 | <0.1 | <0.1 | <0.1 |
21 | 17.8 | 267 | 22.7 |
22 | 20.1 | 140 | 59.7 |
23 | 4.01 | 9.3 | <0.1 |
24 | 41.2 | 9.3 | < 0.1 |
25 | 82.6 | 0.1 | <0.1 |
26 | 64.5 | 0.2 | <0.1 |
27 | 83.1 | 0.8 | 0.9 |
28 | 17.2 | 1.6 | <0.1 |
29 | 38.5 | 6.0 | <0.1 |
30 | 142 | 0.7 | 0.8 |
31 | 135 | 2.2 | 2.4 |
32 | 151 | 1.7 | 8.8 |
33 | 24.5 | <0.1 | 10.4 |
34 | 19.1 | 0.92 | 0.6 |
35 | 7.5 | <0.1 | 1.3 |
36 | 37.4 | 0.39 | 0.2 |
37 | 236 | 6.21 | 2.2 |
38 | 2.3 | - | - |
39 | 13.9 | 0.53 | <0.1 |
40 | 75.2 | <0.1 | <0.1 |
41 | 34.3 | <0.1 | <0.1 |
42 | 33.9 | 205.8 | 7.8 |
43 | 12.6 | 88.4 | 3.70 |
44 | 1.3 | <0.1 | <0.1 |
45 | 6.6 | < 0.1 | < 0.1 |
46 | 1.4 | < 0.1 | < 0.1 |
47 | 2.4 | < 0.1 | < 0.1 |
48 | 1.5 | < 0.1 | < 0.1 |
49 | 29.8 | <0.1 | 3.3 |
50 | 67.4 | 50.5 | 2.7 |
51 | 14.4 | 2.0 | 0.1 |
52 | 44.1 | 7.5 | 0.3 |
53 | 161 | 8.4 | 1.3 |
54 | 30.6 | 1.4 | 0.1 |
55 | 27.1 | 0.7 | 2.4 |
56 | 57.9 | 4.9 | 0.8 |
57 | 11.7 | <0.1 | 0.3 |
58 | 39.1 | 2.6 | 0.2 |
59 | 40.3 | <0.1 | 4.0 |
60 | 106.2 | <0.1 | 8.2 |
61 | 59.8 | <0.1 | 2.8 |
62 | 5.2 | <0.1 | <0.1 |
63 | 15.3 | <0.1 | <0.1 |
64 | 64.6 | 60.1 | 92.9 |
65 | 95.4 | 25.2 | 11.6 |
66 | 15.8 | 172 | 17.2 |
67 | 28.5 | 46.2 | 39.8 |
68 | 27.9 | 8.8 | 107 |
69 | 24.3 | 9.6 | 62.8 |
70 | 15.1 | 71.3 | 64.4 |
71 | 90.1 | 12.7 | 94.7 |
72 | 11.5 | 1.0 | 1.6 |
73 | 22.6 | 5.4 | 3.0 |
74 | 12.9 | 0.9 | 1.0 |
75 | 35.1 | 8.5 | 18.0 |
76 | 10.3 | 47.6 | 11.7 |
77 | 38.7 | 12.2 | 35.5 |
78 | 51.0 | 14.0 | 0.12 |
79 | 41.5 | 4.9 | 1.4 |
80 | 8.1 | 0.0 | 0.1 |
81 | 7.8 | 0.3 | <0.1 |
82 | 9.5 | 1.1 | <0.1 |
83 | 47.3 | 1.3 | 0.4 |
84 | 4.2 | <0.1 | <0.1 |
85 | 4.3 | <0.1 | 0.3 |
86 | 28.4 | 0.4 | 0.2 |
87 | 0.9 | <0.1 | <0.1 |
88 | 9.6 | 0.3 | <0.1 |
89 | 7.1 | 0.7 | <0.1 |
90 | 7.4 | <0.1 | <0.1 |
91 | 31.9 | 16.8 | 0.3 |
92 | 0.8 | <0.1 | 0.4 |
93 | 5.7 | 0.3 | 0.7 |
94 | 0.5 | <0.1 | <0.1 |
95 | 2.1 | 0.4 | <0.1 |
96 | 34.4 | 194.8 | 5.2 |
97 | 10.5 | 62.8 | 2.6 |
98 | 28.1 | 8.2 | 47.1 |
99 | 20.9 | 14.9 | 57.7 |
100 | 42.2 | 12.7 | 118.5 |
101 | 23.2 | 13.9 | 40.1 |
102 | 23.3 | 29.5 | 58.0 |
지속형 결합체 | 천연형 펩타이드 대비in vitro 활성 (%) | ||
vs GLP-1 | vs Glucagon | vs GIP | |
21 | 0.1 | 1.6 | 0.2 |
22 | 0.1 | 0.9 | 0.5 |
42 | 3.1 | 23.1 | 1.2 |
43 | 2.1 | 13.5 | 0.6 |
50 | 15.4 | 6.9 | 0.7 |
77 | 6.7 | 1.7 | 6.6 |
96 | 0.3 | 4.0 | 0.3 |
Claims (18)
- 신경퇴행성 질환의 예방 또는 치료를 위한 약학적 조성물로서,약학적으로 허용되는 부형제와서열번호 1 내지 102 중 어느 하나의 아미노산 서열을 포함하는 펩타이드를 약학적 유효량으로 포함하는 약학적 조성물.
- 제1항에 있어서, 상기 펩타이드는 지속형 결합체의 형태이고, 상기 지속형 결합체는 하기 화학식 1로 표시되는 약학적 조성물:[화학식 1]X - L - F단 이 때 X는 서열번호 1 내지 102 중 어느 하나의 아미노산 서열의 펩타이드이고;L은 에틸렌글리콜 반복 단위를 함유하는 링커이며,F는 면역글로불린 Fc 영역이고,-는 X와 L 사이, L과 F 사이의 공유결합 연결을 나타낸다.
- 제1항 또는 제2항에 있어서, 상기 펩타이드는 그 C-말단이 아미드화된 약학적 조성물.
- 제1항 또는 제2항에 있어서, 상기 펩타이드는 서열번호 21, 22, 42, 43, 50, 64, 66, 67, 70, 71, 76, 77, 96, 97과 100으로 이루어진 군으로부터 선택하는 아미노산 서열을 포함하는 약학적 조성물.
- 제4항에 있어서, 상기 펩타이드는 서열번호 21, 22, 42, 43, 50, 66, 67, 77, 96, 97과 100으로 이루어진 군으로부터 선택하는 아미노산 서열을 포함하는 약학적 조성물.
- 제5항에 있어서, 상기 펩타이드는 서열번호 21, 22, 42, 43, 50, 77과 96으로 이루어진 군으로부터 선택하는 아미노산 서열을 포함하는 약학적 조성물.
- 제1항 또는 제2항에 있어서, 상기 펩타이드 서열은 N-말단으로부터 16번 아미노산과 20번 아미노산은 서로 고리를 형성하는, 약학적 조성물.
- 제2항에 있어서, 상기 L은 폴리에틸렌 글리콜인, 약학적 조성물.
- 제2항에 있어서, 상기 L 내의 에틸렌글리콜 반복 단위 부분의 화학식량은 1 내지 100 kDa 범위에 있는 약학적 조성물.
- 제2항에 있어서, 상기 면역글로불린 Fc 영역은 비당쇄화된 것인, 약학적 조성물.
- 제2항에 있어서, 상기 F는 IgG Fc 영역인, 약학적 조성물.
- 제2항에 있어서, 상기 면역글로불린 Fc 영역은 두 개의 폴리펩타이드 사슬로 이루어진 이량체며, L의 한 말단이 상기 두 폴리펩타이드 사슬 중 하나의 폴리펩티드 사슬에만 연결되어 있는, 약학적 조성물.
- 제2항에 있어서, 상기 결합체는 L의 한쪽 말단이 F의 아민기 또는 티올기와, L의 다른 말단이 X의 아민기 또는 티올기에 각각 반응하여 형성된 공유결합으로 F 및 X에 각각 연결되어 있는 것인, 약학적 조성물.
- 제1항 또는 제2항에 있어서, 상기 신경퇴행성 질환은 파킨슨 질환, 헌팅턴 질환, 알츠하이머 질환, 진행성 핵상 마비(PSP: progressive supranuclear palsy), 다계통 위축증(MSA: multiple system atrophy), 루이체 치매(Lewy body dementia), 파킨슨 질환 치매, 뇌전증, 뇌졸중, 뇌 저산소증, 말초 신경병증, 기억력 손상, 기억력 상실, 건망증 피크(pick)병, 크로이츠펠트-야콥(creutzfeld-kacob)병 및 당뇨병의 부작용에 의한 신경 손상으로 이루어진 군에서 선택된 적어도 하나의 질환인, 약학적 조성물.
- 제14항에 있어서, 상기 신경퇴행성 질환은 알츠하이머 질환인, 약학적 조성물.
- 제14항에 있어서, 상기 신경퇴행성 질환은 파킨슨 질환 또는 뇌졸중인, 약학적 조성물.
- 제1항 또는 제2항에 있어서, 상기 약학적 조성물은 하기 특성 중 하나 이상을 갖는 것인, 약학적 조성물:(i) 도파민 세포 보호 효과;(ii) 미세아교세포 감소;(iii) 알파시누클레인 농도 감소; 또는(iv) 운동 실조 증상 완화.
- 제1항 또는 제2항에 있어서, 상기 약학적 조성물은 하기 특성 중 하나 이상을 갖는 것인, 약학적 조성물:(i) 아밀로이드 베타 단백질 감소; 또는(ii) AGE (advanced glycation end products) 감소.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21872925.9A EP4218791A1 (en) | 2020-09-25 | 2021-09-24 | Therapeutic use, for neurodegenerative diseases, of triple agonist having activity with respect to all of glucagon, glp-1, and gip receptors, or conjugate thereof |
JP2023519285A JP2023543036A (ja) | 2020-09-25 | 2021-09-24 | グルカゴン、glp-1及びgip受容体の全てに対して活性を有する三重活性体またはその結合体の神経退行性疾患の治療用途 |
US18/028,420 US20230355789A1 (en) | 2020-09-25 | 2021-09-24 | Therapeutic use, for neurodegenerative diseases, of triple agonist having activity with respect to all of glucagon, glp-1, and gip receptors, or conjugate thereof |
CN202180072832.2A CN116600831A (zh) | 2020-09-25 | 2021-09-24 | 对胰高血糖素、glp-1和glp受体全部具有活性的三重激动剂或其缀合物用于神经变性疾病的治疗用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20200125195 | 2020-09-25 | ||
KR10-2020-0125195 | 2020-09-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022065897A1 true WO2022065897A1 (ko) | 2022-03-31 |
Family
ID=80845910
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/013005 WO2022065897A1 (ko) | 2020-09-25 | 2021-09-24 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 신경퇴행성 질환의 치료 용도 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20230355789A1 (ko) |
EP (1) | EP4218791A1 (ko) |
JP (1) | JP2023543036A (ko) |
KR (1) | KR20220041764A (ko) |
CN (1) | CN116600831A (ko) |
WO (1) | WO2022065897A1 (ko) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996032478A1 (en) | 1995-04-14 | 1996-10-17 | Genentech, Inc. | Altered polypeptides with increased half-life |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
WO2017116205A1 (ko) | 2015-12-31 | 2017-07-06 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체 |
-
2021
- 2021-09-24 JP JP2023519285A patent/JP2023543036A/ja active Pending
- 2021-09-24 KR KR1020210126416A patent/KR20220041764A/ko unknown
- 2021-09-24 WO PCT/KR2021/013005 patent/WO2022065897A1/ko active Application Filing
- 2021-09-24 CN CN202180072832.2A patent/CN116600831A/zh active Pending
- 2021-09-24 EP EP21872925.9A patent/EP4218791A1/en active Pending
- 2021-09-24 US US18/028,420 patent/US20230355789A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996032478A1 (en) | 1995-04-14 | 1996-10-17 | Genentech, Inc. | Altered polypeptides with increased half-life |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
WO2017116205A1 (ko) | 2015-12-31 | 2017-07-06 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체 |
WO2017116204A1 (ko) | 2015-12-31 | 2017-07-06 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 |
KR20170080522A (ko) * | 2015-12-31 | 2017-07-10 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체 |
Non-Patent Citations (19)
Title |
---|
"Guide to Huge Computers", 1994, ACADEMIC PRESS |
ATSCHUL, [S.] [F., J MOLEC BIOL, vol. 215, 1990, pages 403 |
CAMINS ANTONI, ETTCHETO MIREN, BUSQUETS ORIOL, MANZINE PATRICIA R., CASTRO-TORRES RUBÉN DARIO, BEAS-ZARATE CARLOS, VERDAGUER ESTER: "Triple GLP-1/GIP/glucagon receptor agonists, a potential novel treatment strategy in alzheimer’s disease", EXPERT OPINION ON INVESTIGATIONAL DRUGS , vol. 28, no. 1, 2 January 2019 (2019-01-02), UK , pages 93 - 97, XP009535329, ISSN: 1354-3784, DOI: 10.1080/13543784.2019.1552677 * |
CARILLO, SIAM J APPLIED MATH, vol. 48, 1988, pages 1073 |
DEVEREUX, J. ET AL., NUCLEIC ACIDS RESEARCH, vol. 12, 1984, pages 387 |
EXP NEUROL, vol. 203, no. 2, February 2007 (2007-02-01), pages 293 - 301 |
GRIBSKOV ET AL., NUCL. ACIDS RES, vol. 14, 1986, pages 6745 |
H. NEURATHR. L. HILL: "Atlas of Protein Sequence and Structure", 1979, NATIONAL BIOMEDICAL RESEARCH FOUNDATION, pages: 353 - 358 |
J NEUROSCI RES, vol. 89, no. 7, July 2011 (2011-07-01), pages 1103 - 13 |
JEONG A KIM, SANGDON LEE; SANG HYUN LEE; SUNG YOUB JUNG; YOUNG HOON KIM; IN YOUNG CHOI; SUN JIN KIM: "1107-P: Neuroprotective Effects of HM15211, a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist in the Neurodegenerative Disease Models", DIABETES, vol. 67, no. Suppl. 1, 1 July 2018 (2018-07-01), XP055914732, DOI: 10.2337/db18-1107-P * |
KIM WONKI, JEONG A. KIM; SANG HYUN LEE; SUNGMIN BAE; IN YOUNG CHOI; YOUNG HOON KIM: "1810-P: Effect of HM15211, a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist in the Neurodegenerative Disease Models", DIABETES, vol. 68, no. Suppl. 1, 1 June 2019 (2019-06-01), XP055914735, ISSN: 0097-1472, DOI: 10.2337/db19-1810-P * |
NEEDLEMAN ET AL., J MOL BIOL., vol. 48, 1970, pages 443 |
NEEDLEMANWUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443 - 453 |
PEARSON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 2444 |
PROC NATL ACAD SCI USA., vol. 102, no. 10, 8 March 2005 (2005-03-08), pages 3811 - 6 |
PROC NATL ACAD SCI USA., vol. 106, no. 4, 27 January 2009 (2009-01-27), pages 1285 - 90 |
RICE ET AL., TRENDS GENET, vol. 16, 2000, pages 276 - 277 |
SMITHWATERMAN, ADV. APPL. MATH, vol. 2, 1981, pages 482 |
TAI JINGJING; LIU WEIZHEN; LI YANWEI; LI LIN; HöLSCHER CHRISTIAN: "Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease", BRAIN RESEARCH, vol. 1678, 1 January 1900 (1900-01-01), NL , pages 64 - 74, XP085299561, ISSN: 0006-8993, DOI: 10.1016/j.brainres.2017.10.012 * |
Also Published As
Publication number | Publication date |
---|---|
US20230355789A1 (en) | 2023-11-09 |
CN116600831A (zh) | 2023-08-15 |
KR20220041764A (ko) | 2022-04-01 |
JP2023543036A (ja) | 2023-10-12 |
EP4218791A1 (en) | 2023-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017116205A1 (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체 | |
AU2016287209B2 (en) | Glucagon derivative and a composition comprising a long acting conjugate of the same | |
WO2018004283A2 (ko) | 글루카곤 유도체, 이의 결합체, 및 이를 포함하는 조성물, 및 이의 치료적 용도 | |
WO2012173422A1 (en) | A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof | |
EP2916860A1 (en) | A composition for treating diabetes or diabesity comprising oxyntomodulin analog | |
WO2017116207A1 (ko) | Fgf21 아날로그, fgf21 결합체, 및 이의 용도 | |
WO2018174668A2 (ko) | 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도 | |
WO2020130749A1 (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 및 인슐린을 포함하는 약학 조성물 | |
WO2019066570A1 (ko) | 지속형 단쇄 인슐린 아날로그 및 이의 결합체 | |
WO2021066600A1 (ko) | 글루카곤, 및 glp-1 수용체 및 gip 수용체 이중 작용제를 포함하는 조성물 및 이의 치료학적 용도 | |
WO2021201654A1 (ko) | Glp-2 유도체 또는 이의 지속형 결합체를 포함하는 방사선요법, 화학요법, 또는 이들의 조합으로 유발된 점막염의 예방 또는 치료용 약학적 조성물 | |
WO2020071865A1 (ko) | 글루카곤 및 이를 포함하는 조합물의 치료학적 용도 | |
WO2021145552A1 (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체의 폐질환의 치료 용도 | |
WO2023106845A1 (ko) | 신규한 아디포넥틴 아날로그 및 결합체 | |
WO2022015082A1 (ko) | 글루카곤 유도체 또는 이의 결합체의 간질환에 대한 치료적 용도 | |
WO2022065897A1 (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 신경퇴행성 질환의 치료 용도 | |
WO2022015115A1 (ko) | 3중 작용성 지속형 결합체 또는 3중 작용제를 포함하는 조합물의 치료학적 용도 | |
WO2021133087A1 (ko) | Glp-2 또는 이의 결합체를 포함하는 골 대사성 질환에 대한 예방 또는 치료용 약학적 조성물 | |
WO2021215801A1 (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 고지혈증 예방 또는 치료용 약학적 조성물 및 예방 또는 치료 방법 | |
WO2020214013A1 (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 고지혈증에 대한 치료적 용도 | |
WO2020263063A1 (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 간 질환에 대한 치료적 용도 | |
WO2022080991A1 (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 호흡기 감염 질환의 후유증의 치료 용도 | |
WO2023277620A1 (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도 | |
WO2022065899A1 (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체의 다발성 경화증의 치료 용도 | |
WO2017010790A1 (ko) | 나노입자-유리체 기반 단백질 복합체를 유효성분으로 포함하는 혈관신생억제용 조성물 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21872925 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2023519285 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180072832.2 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021872925 Country of ref document: EP Effective date: 20230425 |